Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population 
Phase II
Protocol CR-6372Version: 2.0 Amendment 1Date: 25 October 2019
Investigational Products: JJV In vestigational senofilcon A Multifocal Contact Lens and     
1-Day Acuvue® Moist Brand Multifocal Contact Lens 
Key Words:  Presbyopia, Multifocal, etafilcon A, senofilcon A, Daily Wear, Daily Disposable, 
Reusable, Dispensing, Randomized Statement of Compliance to proto col, GCP and applicable regulat ory guidelines: 
This trial will be conducted in compliance with the protocol, I SO 14155,
1the International 
Conference on Harmonization Good Clinical Practice E6 (ICH-GCP) ,2the Declaration of 
Helsinki,3 and all applicable regulatory requirements. 
Confidentiality Statement:
This document contains confidential information, which should n ot be copied, referred to, 
released or published without w ritten approval from Johnson & J ohnson Vision Care, Inc. The 
information may not be disclosed to others except to the extent  necessary to obtain Institutional 
Review Board/Independent Ethics Committee approval and informed  consent, or as required 
by International, Federal and St ate Laws, as applicable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that may be added to th is document is also 
confidential and proprietary t o Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner a s the contents of this document.  
CR-6372, v 2.0  
 
Page 1 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS
SPONSOR NAME AND ADDRESS....................................... ................................................ 6  
MEDICAL MONITOR................................................ ............................................................. 6  
AUTHORIZED SIGNATURES.......................................... ..................................................... 7  
CHANGE HISTORY................................................. ............................................................... 8  
SYNOPSIS................................................................................................................................ 9  
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS .......... .......... 14  
1. INTRODUCTION AND BACKGROUND ................................... ................................ 16  
1.1. Name and Descriptions of I nvestigational Products ............. ................................... 16  
1.2. Intended Use of Inve stigational Products................................................................. 16  
1.3. Summary of Findings from Nonclinical Studies ...................................................... 16  
1.4. Summary of Known Risks and Benefits to Human Subjects ......... .......................... 16  
1.5. Relevant Literature References and Prior Clinical Data Relevant  to Proposed Clinical 
Study 17  
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES .................... .................. 18  
2.1. Objectives .................................................... ............................................................. 18  
2.2. Endpoints ..................................................... ............................................................. 18  
2.3. Hypotheses ............................................................................................................... 19  
3. TARGETED STUDY POPULATION ..................................... ...................................... 20  
3.1. General Characteristics ....................................... ..................................................... 20  
3.2. Inclusion Criteria ...................................................................................................... 20  
3.3. Exclusion Criteria ..................................................................................................... 20  
3.4. Enrollment Strategy............................................ ...................................................... 21  
4. STUDY DESIGN AND RATIONALE .................................... ...................................... 21  
4.1. Description of Study Design ................................... ................................................. 21  
4.2. Study Design Rationale ........................................ .................................................... 22  
4.3. Enrollment Target and Study Duration .................................................................... 22  
5. TEST ARTICLE ALLOCATION AND MASKING ........................... .......................... 22  
5.1. Test Article  Allocation ............................................................................................. 22  
5.2. Masking .................................................................................................................... 22  
5.3. Procedures for Maintaining  and Breaking the Masking............ ............................... 23  
6. STUDY INTERVENTION ............................................ ................................................. 23  
6.1. Identity of Test Articles...................................... ...................................................... 23  
6.2. Ancillary Supplies/Products ................................... .................................................. 24  
CR-6372, v 2.0  
 
Page 2 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.3. Administration of T est Articles ............................... ................................................. 24  
6.4. Packaging and Labeling ........................................................................................... 25  
6.5. Storage Conditions ................................................................................................... 25  
6.6. Collection and Stora ge of Samples ............................. ............................................. 25  
6.7. Accountability of Test Articles ............................... ................................................. 25  
7. STUDY EVALUATIONS .............................................................................................. 27  
7.1. Time and Event Schedule ....................................... .................................................. 27  
7.2. Detailed Study Procedures ..................................... .................................................. 33  
VISIT 1 ........................................................................................................................... 33  
VISIT 2 ........................................................................................................................... 39  
VISIT 3 ........................................................................................................................... 44  
VISIT 4 ........................................................................................................................... 47  
VISIT 5 ........................................................................................................................... 52  
VISIT 6 ........................................................................................................................... 58  
FINAL EVALUATION .............................................. .................................................... 60  
7.3. Unscheduled Visits ............................................ ....................................................... 61  
7.4. Laboratory Procedures ......................................... .................................................... 63  
8. SUBJECTS COMPLETION/WITHDRAWAL................................. ............................. 63  
8.1. Completion Criteria .................................................................................................. 63  
8.2. Withdrawal/Discontinuation from the Study ........................................................... 63  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ............. .... 64  
9.1. Systemic Medications .............................................................................................. 64  
10. DEVIATIONS FROM THE PROTOCOL .................................................................. 65  
11. STUDY TERMINATION ............................................. .............................................. 65  
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS ............. . 66 
13. ADVERSE EVENTS ................................................ ................................................... 67  
13.1.  Definitions and Classifications ............................................................................. 67  
13.2.  Assessing Adverse Events ...................................... .............................................. 69  
13.2.1.  Causality Assessment .................................................................................... 69  
13.2.2.  Severity Assessment ........................................... ........................................... 70  
13.3.  Documentation and Follow-Up of Adverse Events ................. ............................. 70  
13.4.  Reporting Adverse Events ...................................... .............................................. 71  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 71  
CR-6372, v 2.0  
 
Page 3 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
 7 2  
13.4.3.  Event of Special Interest ............................................................................... 72  
13.5.  Reporting of Pregnancy ........................................................................................ 73  
14. STATISTICAL METHODS ........................................... ............................................. 73  
14.1.  General Considerations ........................................ ................................................. 73  
14.2.  Sample Size Justification ...................................................................................... 73  
14.3.  Analysis Populations ............................................................................................ 74  
14.4.  Level of Statistical Significance ............................. .............................................. 75  
14.5.  Primary Analysis .............................................. .................................................... 75  
14.6.  Secondary Analysis ............................................ .................................................. 75  
14.7.  Other Exploratory Analyses .................................... ............................................. 75  
14.8.  Interim Analysis ................................................................................................... 76  
14.9.  Procedure for Handling Missing Data and Drop-Outs ............. ............................ 76  
14.10.  Procedure for Reporting Devia tions from Statistical Plan ...... ............................. 76  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING .................... ............ 76  
15.1.  Electronic Case Report Form/Data Collection ..................................................... 76  
15.2.  Subject Record ................................................ ...................................................... 77  
15 15.3  ClinicalTrials.gov ............................................................................................ 77  
16. DATA MANAGEMENT................................................ ............................................. 77  
16.1.  Access to Source Data/Document ................................ ........................................ 77  
16.2.  Confidentiality of Information................................. ............................................. 77  
16.3.  Data Quality Assurance ........................................ ................................................ 78  
17. CLINICAL MONITORING ........................................... ............................................. 78  
18. ETHICAL AND REGULATORY ASPECTS ............................................................ 79  
18.1.  Study-Specific Design Considerations ................................................................. 79  
18.2.  Investigator Responsibility ................................... ................................................ 79  
18.3.  Independent Ethics Committee or Institutional Review Board (IEC /IRB) .......... 79  
18.4.  Informed Consent .............................................. ................................................... 80  
18.5.  Privacy of Personal Data ...................................... ................................................ 81  
19. STUDY RECORD RETENTION......................................... ....................................... 82  
20. FINANCIAL CONSIDERATIONS ...................................... ...................................... 82  
21. PUBLICATION ........................................................................................................... 83  
22. REFERENCES .................................................... ........................................................ 83  
CR-6372, v 2.0  
 
Page 4 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .. ... 84  
APPENDIX B: PATIENT INSTRUCTION GUIDE  (To be provided separately) .......... 116  
APPENDIX C: PACKAGE INS ERT (APPROVED PRODUCT) ....................................... 117  
APPENDIX D: BINOCULAR OVER REFRACTION ......................... .............................. 146  
APPENDIX E: PRESBYOPIC SYMPTOMS QUESTIONNAIRE ................. .................... 147  
APPENDIX F: OCULAR DOMINANCE................................... ......................................... 148  
APPENDIX G: LENS FITTING GUIDE ................................ ............................................. 149  
APPENDIX H:  .................................... 151  
LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS ........................ .......... 152  
EXPANDED SODIUM FLUORESCE IN CORNEAL STAINING ..................  160  
 DETERMINATION OF NEAR ADDITION ............................... ..................... 165  
 NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE ....... 173  
 LENS FITTING CHARACTERISTICS ............................................................ 176  
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS .................... ... 183  
 FRONT AND BACK SURFACE LENS DEPOSIT GRADING PROCEDURE
............................................................................................................................................... 185  
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
............................................................................................................................................... 191  
 BIOMICROSCOPY SCALE .......................................... ................................... 198  
 KERATOMETRY PROCEDURE ..................................................................... 204  
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION ................... ..... 206  
 DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE
............................................................................................................................................... 211  
, PATIENT REPORTED OUTCOMES .............................................................. 215  
 WHITE LIGHT LENS SURFACE WETTABILITY ......................... ............... 217  
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING .............................................................................................................................. 219  
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE PAGE ............ ............ 225  
TABLE OF CONTENTS
Figure 1: Study Flowchart ..................................... ................................................................. 13  
TABLE OF CONTENTS
Table 1: Test Articles ........................................ ...................................................................... 23  
Table 2: Ancilla ry Supplies .................................................................................................... 24  
Table 3: Time and Events ...................................... ................................................................. 27  
Table 4: Disallowed systemic med ications (less than 6 months of continual use). ................ 64
CR-6372, v 2.0  
 
Page 5 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION
Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population Phase 
II
Protocol Number:  CR-6372    Version: 2.0 Date: 25 October 2019    
SPONSOR NAME AND ADDRESS 
Johnson & Johnson Vision Care (JJV)
7500 Centurion Parkway  Jacksonville, FL 32256 
MEDICAL MONITOR
Name:  Thomas R. Karkkainen, OD, MS, FAAO 
Title: Sr. Principal Research OptometristAddress: 7500 Centurion Parkw ay, Jacksonville, Florida 32256 
Email: TKarkkai@its.jnj.com
The Medical Monitor must be notified by the clinical institutio n/site by e-mail, fax, or 
telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may 
be contacted during business hours for adverse event questions. General study related questions 
should be directed towards your a ssigned clinical research asso ciate.
The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.
CR-6372, v 2.0  
 
Page 6 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS 
Protocol Title Clinical Evaluati on of a Reusable Multifocal Opti cal Design 
in a Presbyopic Population Phase II
Sponsor JJVC, 7500 Centurion Par kway, Jacksonville, FL  32256
Clinical Phase Devel opment phase, Phase 2
Trial Registration This study will be registered on ClinicalTria ls.gov.
Test Article(s) Inves tigational Products: JJV  Investigational Multifocal 
Contact Lens manufactured in senofilcon A material.  
Approved Products: 1-Day Acuvue®Moist Brand Multifocal 
Contact Lens.
Wear and Replacement SchedulesWear Schedule: The Test and Control lenses are used as daily wear (note: the Test le ns will be reusable and the 
Control lens daily disposable).   
Replacement Schedule: The Test l ens will be replaced at the 
optimization visit.  The Control lens will be replaced after 
each day of wear as well as t he optimization visit. The Test 
and Control lenses will als o be replaced when lost or 
damaged
Objectives This primary objective  of this pilot study is to eva luate the 
visual performance of the JJV I nvestigational senofilcon A 
Multifocal Contact Lens (Test) made using a new 
manufacturing process by c omparison with 1-Day Acuvue®
Moist Brand Multifocal (Control). 
The secondary objective is t o evaluate the clinical 
performance of the Test lens by  comparisons with the control 
lens in the following areas: 
xVision (subjective) 
xComfort
xSlit Lamp Findings
xPatients’ reported ocular symptoms 
Study Endpoints Primary Endpoints:
Binocular distance, intermediat e and near visual performance 
under different lighting conditions. Secondary Endpoints: 
xOverall quality of vision scores on CLUE scale 
xOverall comfort scores on CLUE scale
xSubject reported ocular symptoms 
xSlit Lamp Findings
CR-6372, v 2.0  
 
Page 9 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Study Design This is a randomized-controlled, sin gle-masked, crossover 
clinical trial.  There are two s tudy lenses. Each lens will be 
dispensed for 3 ± 1 days and the n an optimization visit will 
occur.  The final lens pair w ill be dispensed for 12 ± 2 days 
and the follow-up on the final l ens pair will occur. The 
second study lenses will the n be fit and the above sequence 
repeated.  
See the flow chart at the end of  the synopsis table for the 
schematic of the study vis its and procedures of main 
observations (Figure 1).
Sample Size Up to 48 subjects will  be enrolled  with a target co mpletion 
of 40 subjects.
Study Duration The study will last approximately 2-4 months.
Anticipated Study 
Population Healthy male and fe male volunteers with presbyopia will be
invited to participate in the s tudy. Subjects will be adapted 
soft contact lens wearers in both eyes.  Additional 
information regarding the elig ibility of the population can be 
found in the inclusion/exclusi on criteria outlined below.
Eligibility Criteria Potential subjects must satisfy all the fol lowing criteria to be 
enrolled in the study 
Inclusion Criteria after Screening: 
1. The subject must read, understand, and sign the 
STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to 
the instructions set fort h in this clinical protocol.
3. The subject must be at least 40 years of age and not 
greater than 70 years of a ge at the time of consent.
4. Subjects must own a wearabl e pair of spectacles if 
required for their distance vision. 
5. The subject must be an ada pted soft contact lens 
wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration). 
6. The subject must either already be wearing a 
presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses , etc.) or if not respond 
positively to at least one symptom on the “Presbyopic Symptoms Questionnaire”.
CR-6372, v 2.0  
 
Page 10 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Inclusion Criteria after Baseline:
7. The subject’s distance spherical equivalent refraction 
must be in the range of +1.25 D to +3.75 D in each 
eye.
8.7KHVXEMHFW¶VUHIUDFWLYHF\OLQGHUPXVWEH D in 
each eye.
9. The subject’s ADD power m ust be in the range of 
+0.75 D to +2.50 D. 
10. The subject must have distance best corrected visual 
acuity of 20/20-3or better in each eye. 
Potential subjects who meet any of  the following criteria will 
be excluded from particip ating in the study:  
Exclusion Criteria after Screening:
1. Currently pregnant or lactating. 2. Any active or ongoing oc ular or systemic allergies 
that may interfere with contact lens wear.  
3. Any active or ongoing systemic disease, autoimmune 
disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
4. Any previous, or planned , ocular or intraocular 
surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, cataract surger y, retinal surgery, etc.).
5. A history of amblyopia, strabismus or binocular 
vision abnormality. 
6. Use of any of the following medications within 1 week 
prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines, oral/topical/inhaled anticholinergics, systemic/topicalcorticosteroids. 
7. Use of any ocular medi cation, with the exception of 
rewetting drops. 
8. History of herpetic keratitis.9. History of irregular cornea.10. History of pathological dry eye.11. Participation in any contact lens or lens care product 
clinical trial within 30 days pr ior to study enrollment.
12. Employee or immediate family member of an 
employee of clinical site (e.g., Investigator, Coordinator, Technician).
CR-6372, v 2.0  
 
Page 11 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13. Any known hypersensitivity or allergic reaction to 
Optifree®Replenish®multi-purpose care solution, 
sodium fluorescein or  non- preserved  rewetting drop 
solutions. 
Exclusion Criteria after Baseline: 
14. Clinically significant (Grade 2 or greater) corneal 
edema, corneal vasculari zation, corneal staining, 
tarsal abnormalities or bulb ar injection, or any other 
corneal or ocular abnormalities which would 
contraindicate contact lens wear.
15. Entropion, ectropion, extrusions, chalazia, recurrent 
styes, glaucoma, history of recurrent corneal erosions. 
16. Any current ocular infection or inflammation. 17. Any current ocular abnormality that may interfere 
with contact lens wear.
Disallowed Medications/Interventions  Use of any prescription or over-the-counter (OTC) medications that may affect contact lens wear.  
See section 9.1 for details regarding disallowed systemic 
medications.
Measurements and ProceduresSee Section 7.2 for the d etailed procedures.
Microbiology or Other Laboratory TestingNone
Study Termination The occurrence  of one or more Unanticipated Ad verse 
Device Effect (UADE), or any SAE where relationship to 
study agent cannot be rule d out, will result in stopping 
further dispensing investigati onal product. In the event of a 
UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject (s) and may discuss this with 
the Principal Investigator befo re any further subjects are 
enrolled.
Ancillary Supplies/ Study-Specific MaterialsRewetting drops, lens cases, glass vials, saline, Early Treatment Diabetic  Retinopathy Study (ETDRS) light 
cabinet, logMAR charts, and Near logMAR charts. Optifree
®Replenish®Multipurpose Disinfecting Contact 
Solution.
Principal Investigator(s) and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is included in the study Trial Master File.
CR-6372, v 2.0  
 
Page 12 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS
ADD   Plus Power Required For Near Use 
ADE   Adverse Device EffectAE   Adverse Event/Adverse ExperienceBCVA   Best Corrected Visual AcuityBSCVA  Best Spectacle Corrected Visual AcuityCFR   Code of Federal RegulationsCLUE   Contact Lens User ExperienceCOAS   Complete Ophthalmic Analysis SystemCOM   Clinical Operations ManagerCRA   Clinical Research AssociateCRF   Case Report FormCRO   Contract Research OrganizationCT   Center Thickness
   
D   Diopter DMC   Data Monitoring CommitteeeCRF   Electronic Case Report FormEDC   Electronic Data CaptureETDRS  Early Treatment Dia betic Retinopathy Study
FDA   Food and Drug Administration GCP   Good Clinical PracticeHIPAA  Health Insurance Portability and Accountability Act IB   Investigator’s BrochureICF   Informed Consent Form ICH   International Conference on Harmonization IDE   Investigational Device ExemptionIEC   Independent Ethics Committee IRB   Institutional Review BoardISO   International Organi zation for Standardization 
ITT   Intent-to-TreatJJVC   Johnson & Johnson Vision Care, Inc. LC   Limbus Center LogMAR  Logarithm of Minimal Angle of ResolutionMedDRA
©  Medical Dictionary for Regulatory Activities
MOP   Manual of Procedures NIH   National Institutes of HealthOD   Right Eye
OHRP   Office for Human R esearch Protections 
OHSR   Office for Human Subjects Research
O S    L e f t  E y eOU   Both Eyes PD   Protocol Deviation PHI   Protected Health InformationPI   Principal Investigator
CR-6372, v 2.0  
 
Page 14 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PIG   Patient Instruction Guide 
PQC   Product Qua lity Complaint 
PRO   Patient Reported Outcome QA   Quality Assurance QC   Quality Control SAE   Serious Adverse Event/S erious Adverse Experience
SAP   Statistical Analysis PlanSAS   Statistical Analysis SystemSD   Standard Deviation SOP   Standard Ope rating Procedure 
UADE   Unanticipated Adverse Device EffectUSADE  Unanticipated Serious Adverse Device EffectVA   Visual Acuity
CR-6372, v 2.0  
 
Page 15 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1. INTRODUCTION AND BACKGROUND
Johnson & Johnson Vision (JJV) recently launched a multifocal c ontact lens, 1-DAY
ACUVUE®Moist Multifocal.  The lens is the only marketed soft multifoca l lens to have its 
optical design optimized for the changes that occur in pupil si ze with refractive error.  The 
modality for the lens is daily disposable.  There is a desire t o evaluate the same optical design 
in a reusable modality.  The purpose of this study is to evalua te a multifocal optical design 
manufactured from senofilcon A material and compare the visual performance to the 1-DAY 
ACUVUE®Moist Multifocal. 
1.1. Name and Descriptions of Investigational Products  
Test Lens: JJV Investigationa l senofilcon A Multifocal Contact Lens-The lens has the same 
optical design, diameter , aspheric back surface design as the 1-Day Acuvue® Moist Brand 
Multifocal.  The lens is ma nufactured in senofilcon A.        
Control Lens:  Marketed 1-Day Acuvue® Moist Brand Multifocal Contact Lenses
1.2. Intended Use of Investigational Products
Both lenses are intended to correct spherical refractive error and presbyopia.  The Test lenses 
are intended to be used as a 2-week, reusable, daily wear lens.   The lenses require use of a care 
system to clean and disinfect the  lenses.  The control lenses a re daily wear lenses that are 
disposed of at the end of each wear  cycle. No care system is req uired for the control lenses.   
1.3. Summary of Findings fr om Nonclinical Studies
All previous pre-clinical findings were deemed satisfactory pri or to proceeding with clinical 
trials on humans.  For the most comprehensive nonclinical inform ation regarding JJV 
investigational senofilcon A multifocal refer to the latest vers ion of the Investigator Brochure. 
1.4. Summary of Known Risks and Benefits to Human Subjects
The Investigational multifocal contact lenses are designed as a  continuous asphere providing 
for the correction of refractiv e spherical ammetropia and presby opia.  The material is a silicone 
hydrogel material, senofilcon A.   
The 1-Day Acuvue®Moist Brand Multifocal Contact Lens is a currently marketed pro duct that 
is made of the etafilcon-A material.  The contact lenses are av ailable as continuous aspheres 
providing for the correction of a subjects refractive spherical ammetropia and presbyopia. The intent of the Test lens is daily wear, reusable lens that th e subject wears while awake.  This 
lens is not intended for extende d wear.  Anticipated risks and adverse reactions with this lens 
are similar to other soft daily wear contact lenses used to cor rect presbyopia.  A listing of 
examples of adverse reactions is found in the Section 13 of thi s protocol.  The investigator 
should follow normal clinical guidelines regarding examination and care of subjects who
participate in this trial. For the most comprehensive clinical information regarding the JJV 
Investigational senofilcon A multifocal lens refer to the Invest igator Brochure.  Additional 
CR-6372, v 2.0  
 
Page 16 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
details on the 1-Day Acuvue®Moist Brand Multifocal Contact Lens can be found in the 
package insert in Appendix C.
1.5. Relevant Literature References and Prior Clinical Data Rele vant to Proposed 
Clinical Study
JJV has evaluated the test lenses in the previous clinical stud ies:
A summary of these studies is listed below.
was a dispensing clinical trial with primary end points of logM AR visual acuity at 
fit and CLUE vision scores at 1 week.  The study was a cross-ov er design with a marketed 
product serving as the control.  There were 32 subjects that completed the study as cohort.  The 
Test lens displayed good visual acuity with the mean distance a nd intermediate logMAR acuity 
better than 0.0 and the mean near logMAR acuity better than +0. 1 logMAR.  This with true of 
the acuity at the initial fit as well as the 1 week and 2-week visits in the final lens pair.  There 
were two non-ocular adverse events that occurred during the stu dy that were not related to any 
of the Test lenses. 
was a dispensing parallel-ARM study and had a primary endpoint of logMAR visual 
acuity. There were 149 subjects that completed the study overal l with 37 subjects completing 
in the ARM involving the study lenses that will be used in this  study.  The lenses displayed 
clinically acceptable logMAR visual acuity after approximately 2 weeks of wear with the mean 
bright high contrast binocul ar logMAR acuity of -0.077, -0.083 and 0.049 for distance, 
intermediate and near respectively.  
 had four parallel ARMs with one of the ARMs being the test len ses evaluated in this 
study along with two other investigational test lenses and a co ntrol lens.  For the ARM with 
the lenses tested in this study there were no ocular adverse ev ents reported and one non-ocular 
that was not related t o the test article. 
was a dispensing crossover study on myope subjects and had a pri mary endpoint of 
subject vision response. There wer e 53 subjects that completed the study as cohort.  The test
lenses displayed clinically acceptable logMAR visual acuity aft er approximately 2 weeks of 
wear with the mean bright high c ontrast binocular logMAR acuity  of -0.11, -0.07 and 0.06 for 
distance, intermediate and near respectively.  There was one ad verse event in the study that 
was a non-significant temporal c onjunctival hyperemia in the ri ght eye after removal of their 
lenses. The event resolve d without any treatment.
was a dispensing crossover study on hyperope subjects and had a primary endpoint 
of subject vision response. There were 59 subjects that completed the study as cohort.  The testlenses displayed clinically acceptable logMAR visual acuity aft er approximately 2 weeks of 
wear with the mean bright high c ontrast binocular logMAR acuity  of -0.05, -0.02 and 0.11 for 
distance, intermediate and near respectively.  One subject had a non-ocular serious adverse 
event of dehydration of moderate severity and received treatmen t for this event. Although the 
event was reported as resolved, the subject was permanently dis continued the study. The 
investigator considered the event  to be not related to the stud y article/study procedure. Three 
episodes of ocular adverse events were reported. One subject ha d an ocular AE of non-
CR-6372, v 2.0  
 
Page 17 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Secondary Endpoints: 
xOverall quality of vision scores on CLUE scale 
xOverall comfort scores on CLUE scale
xSubject reported ocular symptoms 
xSlit Lamp Findings
Other Endpoints(s)  
xLens fitting characteristics (lens centration, lens movement, o verall lens fitting 
acceptability)
xAverage daily wear time (in Hours) 
xCorneal staining 
xOcular redness (bulbar and limbal) 
xSummary of number of lenses need ed to fit (optimize) the subjec t
xLens deposits 
xOverall handling scores on CLUE scale 
xProduct performance survey questionnaire  
Adverse events, number and reas ons for discontinuation, number and reasons for unscheduled. 
lens replacement including l ens damage will be monitored and de scriptively evaluated. 
CLUE™is a validated patient reporte d outcomes (PRO) questionnaire to  assess patient-
experience attributes of soft c ontact lenses (comfort, vision, handling, and packaging) in a 
contact-lens wearing population in the US, ages 18-65. Derived CLUE™ scores using Item 
Response Theory (IRT) follow a normal distribution with a popul ation average score of 60 
(SD 20), where higher scores indicate a more favorable/positive  response with a range of 0-
120. A 5-point increase in an aver age CLUE™ score translates in to 10% shift in the 
distribution of scores for popula tion of soft contact lens wear ers.7
2.3. Hypotheses
Primary Hypotheses:
The Test lens will be non-inferio r to the Control lens with respect to binocular contact lens-
corrected visual performance at n ear, intermediate and distance  under high luminance high 
contrast, Dim luminance high contrast and high luminance low co ntrast conditions. A non-
inferiority margin of 0.05 on logMAR scale will be used. 
Secondary Hypotheses:
No secondary hypotheses will be  tested. All secondary endpoints  will be evaluated with 
summary tables (see Section 14 for more details). The following  will be calculated: 
xAverage (SD) comfort scores on CLUE scale by study lens at each  follow-up visit 
xProportion of eyes with clinically significant (Grade 3 or 4) s lit lamp findings. 
xProportion of eyes with reported ocular symptoms.  
CR-6372, v 2.0  
 
Page 19 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
3. TARGETED STUDY POPULATION
3.1. General Characteristics 
Healthy male and female subjects who are habitual soft contact lens wearers will be recruited.  
Subjects will be at least 40 years of age and not older than 70 years of age.  They will be 
hyperopic and have presbyopia .    
3.2. Inclusion Criteria
Potential subjects must satisfy all of the following criteria t o be enrolled in the study:
Inclusion Criteria after Screening: 
1. The subject must read, unders tand, and sign the STATEMENT OF INFORMED 
CONSENT and receive a fully  executed copy of the form.
2. The subject must appear able and willing to adhere to the ins tructions set forth in this 
clinical protocol.
3. The subject must be at least  40 years of age and not greater t han 70 years of age at the 
time of consent. 
4. Subjects must own a wearable pair of spectacles if required f or their distance vision.
5. The subject must be an adapte d soft contact lens wearer in bo th eyes (i.e. worn lenses 
a minimum of 2 days per week for  at least 8 hours per wear day, for 1 month or more 
duration). 
6. The subject must either alread y be wearing a presbyopic contact lens correction (e.g., 
reading spectacles over contact l enses, multifocal or monovisio n contact lenses, etc.) 
or if not respond positively to at least one symptom on the “Pr esbyopic Symptoms 
Questionnaire” (Appendix E). 
Inclusion Criteria after Baseline: 
7. The subject’s distance spheri cal equivalent refraction must b e in the range of +1.25 D 
to +3.75 D in each eye.
8.7KHVXEMHFW¶VUHIUDFWLYHF\OLQGHUPXVWEH D in each eye.
9. The subject’s ADD power must  be in the range of +0.75 D to +2 .50 D. 
10. The subject must have distance  best corrected visual acuity of 20/20-3 or better in 
each eye.
3.3. Exclusion Criteria
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study: 
Exclusion Criteria after Screening:
1. Currently pregnant or lactating. 
2. Any active or ongoing ocular or  systemic allergies that may i nterfere with contact 
lens wear.  
CR-6372, v 2.0  
 
Page 20 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
3. Any active or ongoing systemic disease, autoimmune disease, o r use of medication, 
which may interfere with contact lens wear. This may include, b ut not be limited to, 
diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, a cne rosacea, Stevens-
Johnson syndrome, and immunosuppressive diseases or any infecti ous diseases (e.g. 
hepatitis, tuberculosis). 
4. Any previous, or planned, ocular or intraocular surgery (e.g.  radial keratotomy, PRK, 
LASIK, lid procedures, cataract surgery, retinal surgery, etc.) .
5. A history of amblyopia, str abismus or binocular vision abnormality. 
6. Use of any of the following medications within 1 week prior t o enrollment: oral retinoid 
isotretinoin (e.g. Accutane), o ral tetracyclines, oral phenothiazines, oral/topical/inhaled
anticholinergics, systemic/topical corticosteroids. 
7. Use of any ocular medicati on, with the exception of rewetting drops. 
8. History of herpetic keratitis.
9. History of irregular cornea.10. History of pathological dry eye.11. Participation in any contact lens or lens care product clini cal trial within 30 days prior 
to study enrollment.
12. Employee or immediate family member of an employee of clinical site (e.g., 
Investigator, Coordinator, Technician). 
13. Any known hypersensitivity or allergic reaction to Optifree
®Replenish®multi-
purpose care solution, sodium f luorescein or non-preserved rewe tting drop solutions. 
Exclusion Criteria after Baseline: 
14. Clinically significant (Grad e 2 or greater) corneal edema, co rneal vascularization, 
corneal staining, tarsal abnor malities or bulbar injection, or any other corneal or 
ocular abnormalities which would contraindicate contact lens we ar. 
15. Entropion, ectropion, extrusions, c halazia, recurrent styes, glaucoma, history of 
recurrent corneal erosions.
16. Any current ocular infection or inflammation. 17. Any current ocular abnormality  that may interfere with conta ct lens wear.
3.4. Enrollment Strategy
Study subjects will be recruited from the Institution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional R eview Board (IRB) approved 
materials.
4. STUDY DESIGN AND RATIONALE
4.1. Description of Study Design
The clinical study is a randomized-controlled, single-masked, c ross-over clinical trial.  There 
are two study lenses. Each lens will be dispensed for 3±1 days an d an optimization visit will 
occur.  The final lens pair will be dispensed for 12±2 days and the follow-up on the final lens 
pair will occur. The second study lenses will then be fit and th e above sequence repeated.  
CR-6372, v 2.0  
 
Page 21 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
4.2. Study Design Rationale 
The study is intended to compare  two study lens types and the i nitial performance, in terms of 
the subjective response after a period of lens dispensing.  The  lenses are dispensed to determine 
the subjective responses and the c omparison is made after a tot al of 14-20 days of wear.   
The cross-over study design was chosen to control for variables  that may impact the lens 
performance between subjects.  A washout period will be used to  minimize the chances of a
significant carry over effect impacting the primary/secondary en dpoints measured in the study.
4.3. Enrollment Target and Study Duration
Up to 48 eligible subjects will be enrolled with 40 targeted to complete the study.  The 
anticipated study duration i s approximately 3 months.
5. TEST ARTICLE ALLOCATION AND MASKING
5.1. Test Article Allocation 
The study lenses will be worn in a bilateral and random fashion using a 2×2 crossover design 
with 2 lens types and 2 periods.  Usi ng a computer-generated ra ndomization scheme provided 
by the study biostatistician, each subject will randomly be ass igned to one of two unique 
sequences (Test/Control or Cont rol/Test).  Randomization will b e stratified by site.
Permuted block randomization will  be used to avoid bias in the assignment of subjects to 
treatment, and to enhance the validity of statistical compariso ns across treatment groups. Each 
block will contain two different lens trial sequences.
Randomization must be performed a t the initial visit. The follo wing must have occurred prior 
to randomization: 
• Informed consent has been obtained • It has been determined that th e subject meets all the inclusi on / exclusion criteria
• Subject history and baseline in formation has been collected 
The order of lens wear will be based on the randomization schem e assigned to the study site.   
The study site will follow the randomization scheme provided an d will complete enrollment 
according to the randomization list and will not pre-select or assign subjects.
5.2. Masking
This is a single-masked (partial) study with the subjects being masked. Subjects will be aware that there are differences in modalities between lens types how ever they will not be told 
anything regarding the optical design other than the design is i ntended to correct for their 
spherical refractive error and presbyopia.  Subjects will be un aware of the identity of the
assigned investigationa l products. Investigators and clinical si te personnel involved in the data 
collection will be aware of the ide ntity of the assigned investig ational products.  
CR-6372, v 2.0  
 
Page 22 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.4. Packaging and Labeling
The test articles will be packaged in blisters, as the primary packaging. The test article will be 
over-labeled to mask the subject to the identity of the lens. T he test articles will be in 
investigational cartons sealed with a tamper evident seal, comm ercial cartons, or in plastic bags 
as the secondary packaging form. The sample study label is shown  below: 
6.5. Storage Conditions 
Test articles will be maintained at ambient temperatures at the  clinical site. Test articles must 
be kept under secure conditions. 
6.6. Collection and Storage of Samples 
When possible, any lens or test article associated with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial wi th moderate solution pending 
directions from the sponsor f or potential return to JJVC. 
6.7. Accountability of Test Articles
JJVC will provide the Investigator with sufficient quantities o f study articles and supplies to 
complete the investigation. The I nvestigator is asked to retain  all lens shipment documentation 
for the test article accountability records. 
Test articles must be  kept in a locked storage cabinet, accessible only to those assigned by the 
Investigator for dispensing. The Investigator may delegate this activity to authorized study site 
personnel listed on the Site Deleg ation Log. All test articles must be accounted. This includes:
1. What was dispensed for the subject for trial fitting, to wear  out of the office, or issued 
for the subject to replace appropriately between visits.  
2. What was returned to the Investigator unused, including expire d or malfunctioning 
product. 
3. The number and reason fo r unplanned replacements. 
The Investigator will collect all unused test articles from the  subjects at the end of the subject’s 
participation. Subject returned unused test articles must be se parated from the clinical study 
inventory of un-dispensed test a rticles and must be labeled wit h the subject number and date 
of return. Following final reconciliation of test articles by t he monitor, the Investigator or 
monitor will return all unused test articles to JJVC.
CR-6372, v 2.0  
 
Page 25 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
If there is a discrepancy betw een the shipment documents and th e contents, contact the study 
monitor immediately . 
 Site Instructions for Test Article Receipt and Test Article 
Accountability for additional information. 
CR-6372, v 2.0  
 
Page 26 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
read a book, magazine or similar for near 
vision.  
1.25 Study Lens Distance 
and Near Visual AcuityMeasure the distance and near visual acuity OD, OS and OU.  Record the results. 
Note:  Use the ETDRS 2000 Series Chart 1 or 
2 near card placed at 40 cm to measure the 
Near visual acuity
1.26 Distance Over-
Refraction andDistance Visual AcuityPerform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.  The distance over-refraction may also be refined under binocular  conditions.  Record 
the results.  The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.   
1.27 Lens Fit Assessment Evaluate and grade lens centration, prim ary 
gaze movement, upgaze movement and tightness (push-up test). 
xThe subject should not proceed to wear 
the lenses if any of the following is observed: 
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement (excessive or insufficient) in all three
movement categories (primary gaze, upgaze, and push-up). 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.
1.28 Modifications If the subject reports unsatisfactory vision, or
is unable to obtain 20/30 distance visual 
acuity OU with the lenses then a modification
must be attempted. If the subject reports 
satisfactory vision with the lenses a modification is not required, however at the Investigator’s discretion and based upon their
findings on the measured visual acuity and/orAppendix 
G (Fitting Guide) 
CR-6372, v 2.0  
 
Page 36 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
over- refraction the investigator may make a 
modification. 
Up to two attempts a t modification are 
permitted if necessary, in  order to achieve an 
acceptable distance and near binocular 
performance for the s ubject, and to enable 
them to wear that particular lens type.  Follow the fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.   If modifications are  required steps 1.21-1.27 
will be repeated for each modification. 
1.29 Post-Fit PRO (MRD)
Questionnaire The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.
1.30 Distance and Near 
Exit Visual AcuityDistance and near Snelle n visual acuity will 
be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU. 
Note: The distance visu al acuity must be at 
least 20/30 OU for the lenses to be 
dispensed. 
1.31 Dispensing Criteria The len ses will be dispensed for 2-4 day s.
xDistance Snellen acuity equal to or 
better than 20/30 OU 
xSubject must indicat e that the vision is 
acceptable.
xSubject must indicate that the comfort of 
the lenses is acceptable.
xLenses must have an acceptable general lens fit.
1.32 Patient Instructions
for Daily Disposable 
Lenses (if 
applicable)Instruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
xOnly enough lenses will be dispensed to 
the subject to wear for the required 
CR-6372, v 2.0  
 
Page 37 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
number of days until their follow-up visit. 
No additional lenses  will be dispensed. 
xA new lens will be  opened and worn each 
day.
xInstruct the subject to bring back all unworn study lenses. 
xNo cleaning or disinfecting solutions will 
be used. If determined necessary by the 
Investigator sterile non-preserved 
rewetting drops may be  dispensed to be 
used as needed for dryness. 
xSubjects will be instr ucted to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
xSubjects will be instr ucted to wear their 
glasses when not wearing the study lenses .
xA patient instruc tion booklet will be 
provided. 
Note: In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement. As much as reasonably possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial 
with sterile saline, and returned to the Sponsor.
1.33 Patient Instructions 
for Daily Reusable 
Wear Lenses (if applicable)Instruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
xOPTI-FREE
®Replenish®solution will be 
used in a rub regime t o disinfect and store 
the lenses each night in the lens case 
provided.  
xIf determined necessary by the 
Investigator sterile non-preserved 
rewetting drops may be  dispensed to be 
used as needed for dryness. 
CR-6372, v 2.0  
 
Page 38 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Note: Subjects must have worn lenses for at 
least 6 hours per day  
To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.
2.4 PRO (CLUE) 
Questionnaire   The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.  
2.5 Ocular Symptoms Subjects will respond to a verbal open-ended 
symptoms questionnaire. 
2.6 Subjective 
AcceptanceRecord whether the s ubject’s distance and 
near vision with the lenses is acceptable.
2.7 Distance and Near 
Entrance Visual AcuityMeasure the distance and near visual acuity OD, OS and OU to the nearest letter.  Record the results.
For near measures use the ETDRS 2000 
Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU.
2.8 Distance Over-
Refraction and Distance Visual AcuityPerform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.  The distance over-refraction may also be refined under binocular conditions.  Record the results and distance visual acuity OD and OS.The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.   
2.9 Determination of 
Lens OptimizationIf the subject reports unsatisfactory vision, or
is unable to obtain 20/30 distance visual 
acuity OU with the lenses then a modification
must be attempted.  
If the subject reports satisfactory vision withthe lenses a modification is not required, however at the Investigator’s discretion and 
based upon their findings on the measured 
visual acuity and/or over- refraction the investigator may make a modification. 
Up to two attempts a t modification are 
permitted if necessary, in  order to achieve an Appendix G(FittingGuide)  
CR-6372, v 2.0  
 
Page 40 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
If any of these slit lamp findings are Grade 3
or higher, an AE must be recorded. All AEs must be followed to resolution.  
If the clearance of the fluorescein needs to be 
expedited, preservative-free rewetting drops 
may be instilled.  
2.14 Insertion of Study 
LensesDispense the subject a new pair of lenses that match the distance and ADD power of the lenses that were r emoved in Step 2.12 above.  
2.15 PRO (MRD)
Questionnaire The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.
2.16 Distance and Near 
Exit Visual AcuityDistance and near Snelle n visual acuity will 
be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU.
Note: The distance visu al acuity must be at 
least 20/30 OU for the lenses to be 
dispensed.
2.17 Dispensing Criteria The len ses will be dispensed for 10-14 da ys.
xDistance Snellen acuity equal to or 
better than 20/30 OU 
xSubject must indicat e that the vision is 
acceptable.
xSubject must indicate that the comfort 
of the lenses is acceptable.
xLenses must have an acceptable general 
lens fit.
2.18 Patient Instructions
for Daily 
Disposable LensesInstruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
xOnly enough lenses will be dispensed to 
the subject to wear for the required 
number of days until their follow-up visit. 
No additional lenses  will be dispensed. 
CR-6372, v 2.0  
 
Page 42 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xA new lens will be  opened and worn each 
day.
xInstruct the subject to bring back all 
unworn study lenses. 
xNo cleaning or disinfecting solutions will 
be used. If determined necessary by the Investigator sterile non-preserved rewetting drops may be  dispensed to be 
used as needed for dryness. 
xSubjects will be instr ucted to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
xSubjects will be instructed to wear their 
glasses when not wearing the study 
lenses .
xSubjects will be instructed to bring their 
habitual contacts or spectacles to the next 
visit. 
Note: In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement. As much as reasonably possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor. If lens damage is present, complete the Product Quality Complaint Form. The lens will be st ored in labeled vial 
with sterile saline, and returned to the Sponsor.
2.19 Patient Instructions 
forDaily Reusable
Wear LensesInstruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
xOPTI-FREE®Replenish®solution will be 
used in a rub regime t o disinfect and store 
the lenses each night in the lens case 
provided.  
xIf determined necessary by the Investigator sterile non-preserved rewetting drops may be  dispensed to be 
used as needed for dryness. 
CR-6372, v 2.0  
 
Page 43 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
(40 cm).
Note:
xThe room illuminance must be between 7.3 and 7.9 EV (394-597 lux).
xDistance, HC-1 Chart luminance Acceptable Range 10.5-10.7 EV (181-208 cd/m2). 
xGuillon-Poling, Near Chart Luminance Acceptable Range 10.8-11.1 EV (223-274 cd/m2). 
xDo not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)
3.9 Binocular Distance 
Over-refraction and 
Distance Visual AcuityPerform a binocular  over-refraction and 
record the OD and OS results and distance visual acuity.   Note: No lens changes are allowed based on the over-refraction.  Appendix D
3.10 Lens Fit Assessment Evaluate and grade lens centration, prim ary 
gaze movement, upgaze movement and tightness (push-up test). 
xThe subject should not proceed to wear 
the lenses if any of the following is observed: 
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement (excessive or insufficient) in all three
movement categories (primary gaze, upgaze, and push-up). 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form. 
3.11 Lens Deposits Grade and rec ord the amount of front and 
back surface lens deposits for both eyes.
3.12 Lens Wettability Grade the  wettability of the lenses.
3.13 Collection of 
unworn lenses (if applicable)Collect unworn lenses returned by the subject.
CR-6372, v 2.0  
 
Page 46 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
4.9 Lens Insertion Subjects will insert the lenses themselves. If  
the lens is uncomfortable, inspect for damage 
and remove, reinsert or replace as necessary.
Damaged lenses will be stored in labeled vial 
with sterile saline, and  clearly differentiated 
from the other worn lenses that will be shipped back to the Sponsor. Complete the Quality Product Complaint form.
4.10 Lens Settling Allow the st udy lenses to settle for a 
minimum of 10 minutes.
4.11 Determine Visual 
SatisfactionDetermine if the subject’s vision is acceptable with the lenses.  Allow the subject to look down a hallway or out  of a window for 
distance vision assessme nts, and for them to 
read a book, magazine or similar for near vision.  
4.12 Study Lens Distance 
and Near Visual AcuityMeasure the distance and near visual acuity OD, OS and OU.  Record the results. 
For near measures use the ETDRS 2000 
Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU.
4.13 Distance Over-
Refraction and Distance Visual AcuityPerform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.  The distance over-refraction may also be refined under binocular  conditions.  Record 
the results.  The results of the distance over-
refraction may also be checked for the impact 
on near vision under monocular and/or binocular conditions.   
4.14 Lens Fit Assessment Evaluat e overall lens fit acceptance 
(acceptable or unacceptable) based on centration, movement  and other fitting 
characteristics.
An unacceptable fit is deemed by one of the 
following criteria: 
xlimbal exposure at primary gaze or with extreme eye movement;
xedge lift;
xexcessive movement in primary and up gaze; or 
CR-6372, v 2.0  
 
Page 49 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xinsufficient movement in all three of 
the following conditions: primary gaze, up gaze, and Josephson push up. 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form.
4.15 Modifications If the subject reports unsatisfactory vision, or
is unable to obtain 20/30 distance visual 
acuity OU with the lenses then a modificationmust be attempted.  If the subject reports satisfactory vision with
the lenses a modification is not required, 
however at the Investigator’s discretion and 
based upon their findings on the measured 
visual acuity and/or over- refraction the 
investigator may make a modification. 
Up to two attempts a t modification are 
permitted if necessary, in  order to achieve an 
acceptable distance and near binocular performance for the s ubject, and to enable 
them to wear that particular lens type.  Follow the fitting guide allowing for at least 10minutes of settling time between each lens modification attempted.   If modifications are  required steps 4.8-4.14 
will be repeated for each modificationAppendix G (Fitting Guide) 
4.16 Post-Fit PRO (MRD) 
Questionnaire The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.
4.17 Distance and Near 
Exit Visual AcuityDistance and near Snelle n visual acuity will 
be measured for each eye with the study contact lenses in place. For near measures use the ETDRS 2000 Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU. 
Note: The distance visu al acuity must be at 
least 20/30 OU for the lenses to be 
dispensed. 
4.18 Dispensing Criteria The len ses will be dispensed for 2-4 day s.
CR-6372, v 2.0  
 
Page 50 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xDistance Snellen acuity equal to or 
better than 20/30 OU 
xSubject must indicat e that the vision is 
acceptable.
xSubject must indicate that the comfort of 
the lenses is acceptable.
xLenses must have an acceptable general lens fit.
4.19 Patient Instructions 
for Daily Disposable 
Lenses (if 
applicable)Instruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
xOnly enough lenses will be dispensed to 
the subject to wear for the required 
number of days until their follow-up visit. No additional lenses  will be dispensed. 
xA new lens will be  opened and worn each 
day.
xInstruct the subject to bring back all unworn study lenses. 
xNo cleaning or disinfecting solutions will 
be used. If determined necessary by the 
Investigator sterile non-preserved 
rewetting drops may be  dispensed to be 
used as needed for dryness. 
xSubjects will be instr ucted to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
xSubjects will be instr ucted to wear their 
glasses when not wearing the study lenses .
Note:   In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.  As much as reasonably possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form. The lens will be stored in labeled vial with sterile saline, and returned to the Sponsor.
CR-6372, v 2.0  
 
Page 51 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5.1 Adverse Events and 
Concomitant 
Medications ReviewReview the subject’s concomitant medications and record any changes from the previous study visit. Record any adverse even ts or medical history 
changes from the previous study visit.
5.2 Wear time and 
Comfortable Wear time with Study lensesRecord the hours the subject has worn the study lenses and the comfortable wear time on the day of follow-up. 
5.3 Compliance Record the subject’s compliance with 
wearing the study lenses.  
Note:  Subjects must have worn lenses for at 
least 6 hours per day  
To be counted as a day of wear at this visit the Subject must have worn the study lenses for 6 hours prior to the visit.
5.4 PRO (CLUE)
Questionnaire  The subject will evaluate the vision characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO questionnaire.  
5.5 Ocular Symptoms Subjects will respond to a verbal open-ended 
symptoms questionnaire
5.6 Subjective 
AcceptanceRecord whether the subject’s distance and near vision with the lenses is acceptable.
5.7 Distance and Near 
Entrance Visual AcuityDistance and near Snelle n visual acuity will 
be measured for each eye with the study contact lenses in place. 
For near measures use the ETDRS 2000 
Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU. 
5.8 Distance Over-
Refraction and Distance Visual AcuityPerform a distance over-refraction OD and OS using loose lenses outside of the phoropter under ambient room illumination.  The distance over-refraction may also be refined under binocular conditions.  Record the results and distance visual acuity OD and OS.  The results of the distance over-refraction may also be checked for the impact on near vision under monocular and/or binocular conditions.   
CR-6372, v 2.0  
 
Page 53 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5.9 Determination of 
Lens OptimizationIf the subject reports unsatisfactory vision, or
is unable to obtain 20/30 distance visual 
acuity OU with the lenses then a modification
must be attempted.  If the subject reports satisfactory vision withthe lenses a modification is not required, 
however at the Investigator’s discretion and 
based upon their findings on the measured 
visual acuity and/or over- refraction the 
investigator may make a modification. 
Up to two attempts a t modification are 
permitted if necessary, in  order to achieve an 
acceptable distance and near binocular 
performance for the s ubject, and to enable 
them to wear that particular lens type.  Follow the fitting guide and steps 4.8-4.14 in Visit 4 Fitting, allowing for at least 10 minutes of settling time between each lens modification.Appendix G(Fitting Guide)  
5.10 Lens Fit Assessment Evaluate and grade lens centration, prim ary 
gaze movement, upgaze movement and tightness (push-up test).
The subject should not pr oceed to wear the 
lenses if any of the following is observed: 
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement 
(excessive or insufficient) in all three
movement categories (primary gaze, 
upgaze, and push-up). 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, perform a slit-lamp evaluation, and complete the Final Evaluation form. 
5.11 Collection of 
unworn lenses (if applicable)Collect unworn lenses returned by the subject when lens power has been optimized  
Note:  If lens power was not changed allow 
the subject to use the unworn lenses 
dispensed at Visit 4 and dispense enough 
CR-6372, v 2.0  
 
Page 54 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xLenses must have an acceptable general 
lens fit.
5.18 Patient Instructions 
for Daily 
Disposable LensesInstruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.
xOnly enough lenses will be dispensed to 
the subject to wear for the required 
number of days until their follow-up visit. No additional lenses  will be dispensed. 
xA new lens will be  opened and worn each 
day.
xInstruct the subject to bring back all unworn study lenses. 
xNo cleaning or disinfecting solutions will 
be used. If determined necessary by the 
Investigator sterile non-preserved 
rewetting drops may be  dispensed to be 
used as needed for dryness. 
xSubjects will be instr ucted to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
xSubjects will be instr ucted to wear their 
glasses when not wearing the study lenses .
xSubjects will be instructed to bring their habitual contacts or spectacles to the next visit. 
  
Note:   In the event a lens is lost or damaged, 
the subject will return to the investigator site for replacement. As much as reasonably possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial with sterile saline, and returned to the Sponsor.
5.19 Patient Instructions 
for Daily Reusable 
Wear LensesInstruct the Subject  the following:
xThe lenses will be w orn on a daily wear 
basis.  
CR-6372, v 2.0  
 
Page 56 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xOPTI-FREE®Replenish®solution will be 
used in a rub regime t o disinfect and store 
the lenses each night in the lens case 
provided.  
xIf determined necessary by the Investigator sterile non-preserved rewetting drops may be  dispensed to be 
used as needed for dryness. 
xSubjects will be instr ucted to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
xSubjects will be instr ucted to wear their 
glasses when not wearing the study lenses .
xSubjects will be instructed to bring their habitual contacts or spectacles to the next visit. 
Note:   In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.  As much as reasonably possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial with sterile saline, and returned to the Sponsor.
5.20 Schedule 
Follow-up The subject will be sch eduled to return for 
their follow-up appointment in 12±2 days.
Note:  To count the follow-up visit as a day of 
wear the Subject must have worn the study 
lenses for 6 hours prior to the visit.
CR-6372, v 2.0  
 
Page 57 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LC#3
Near, Bright IlluminanceReduced Guillon-Poling Charts   
Intermediate (64 cm) High Contrast and Low ContrastNear (40 cm) High Contrast and Low Contrast
Distance, Dim Illuminance (with Distance
goggles) 
High Contrast ETDRS Charts   
4M-HC#4, HC#5, HC#6Near, Dim Illuminance (with Near goggles)
Reduced Guillon-Poling chartsHigh Contrast Intermediate (64 cm) and Near (40 cm). 
Note:
xThe room illuminance must be between 7.3 and 7.9 EV (394-597 lux).
xDistance, HC-1 Chart luminance Acceptable Range 10.5-10.7 EV (181-208 cd/m2). 
xGuillon-Poling, Near Chart Luminance Acceptable Range 10.8-11.1 EV (223-274 cd/m2). 
xDo not use the Mesopic filter for Dim luminance (Dim luminance will be simulated by using the goggles)
6.9 Binocular Distance 
Over-refraction and 
Distance Visual AcuityPerform a binocular  over-refraction and 
record the OD and OS results and distance visual acuity.   Note: No lens changes are allowed based on the over-refraction.   Appendix D
6.10 Lens Fit Assessment Evaluate and grade lens centration, prim ary 
gaze movement, upgaze movement and tightness (push-up test). 
The subject should not pr oceed to wear the 
lenses if any of the following is observed: 
xpresence of limbal exposure (appearance 
of clear cornea) in any gaze
xpresence of edge lift
xpresence of unacceptable movement (excessive or insufficient) in all three
CR-6372, v 2.0  
 
Page 59 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
10. DEVIATIONS FROM THE PROTOCOL
Investigator will notify study sponsor upon identification of a  protocol deviation. Protocol 
deviations must be reported to  the sponsor within 24 hours afte r discovery of the protocol 
deviation. The Investigator will report deviations per IRB/IEC requirements. All deviations 
will be tracked and corrective ac tions implement ed as appropria te.  
If it becomes necessary for the Investigator to implement a dev iation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may imp lement the deviation 
immediately without notification to the sponsor. Within 24 hour s after the implemented 
deviation, the Investigator mus t notify and provide the rationa le to the Sponsor and, as 
required, the IEC/IRB.  
If the deviation potentially impacts the safety of patient or c hanges the technical integrity of 
the study then it must be reporte d to IEC/IRB. This is a "Major Deviation".   
Minor deviations have n o substantive effect on patient safety o r technical integrity of the 
study. They are often logistical i n nature. The informed consent  must also not be contradicted 
by the deviation. Protocol waivers are prohibited 
11. STUDY TERMINATION
The occurrence of one or more Unanticipated Serious Adverse Dev ice Effect (USADE), or 
any SAE where the relationship to study agent cannot be ruled o ut, may result in stopping 
further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask 
the treatment regimen for the subject(s) and will discuss this with the Investigator before any 
further subjects are enrolled.
The Sponsor will determine when a study will be stopped. The Pr incipal Investigator always 
has the discretion to initiate stopping the study based on pati ent safety or if information 
indicates the study’s results are compromised. JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The 
study can be terminated by the Principal Investigator at the individual clinical site due to specific clinical observations, if in their opinion, after a di scussion with JJVC, it is determined 
that it would be unwise to con tinue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk,  the investigation, or that part 
of the investigation presenting the risk, will be terminated as  soon as possible. 
Should the study be terminated (either prematurely or as schedu led), the Investigator will 
notify the IEC/IRB and Regulato ry Authority as required by loca l regulatory requirements.
CR-6372, v 2.0  
 
Page 65 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC ) refers to any written, electr onic, or oral communication 
that alleges deficiencies related to the identity, quality, dur ability, reliability, safety, 
effectiveness or performance of test articles after they have b een released for clinical trial use.  
Potential complaints may come from a variety of sources includi ng but not limited to subjects, 
clinical research associates (CRA), clinical operations manager s (COM), medical monitors, 
and site personnel, etc . The following are not considered produ ct quality complaints: 
xSubject satisfaction inquiries r eported via “Subjective Questio nnaires” and “Patient 
Reported Outcomes (PRO).” 
xClinical test articles that are stored improperly or damaged af ter receipt at the 
investigational site. 
xLens replacements that occur due to drops/fall-outs. 
xDamage deemed by clinicians or clinical staff to be caused by h andling by the user, 
and not indicative of a quality deficiency (i.e. tears, rips, e tc.), only in situations where 
there is no deficiency alleged by the subject. 
Within 24 hours of site personnel be coming aware that a PQC has  occurred, the PQC must be 
recorded in the EDC system, which will trigger an automatic ema il notification to the 
appropriate COM/CRA and Clinical QA representative. In cases wh ere the EDC system in use 
is not configured to send automatic notifications or when an ED C system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery  that a PQC has occurred.   
Upon receipt of the EDC notific ation, the COM/CRA will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/ recorded in the EDC System (Dat e of Sponsor 
Awareness). 
xWho received the complaint. 
xStudy number. 
xClinical site information (c ontact name, site ID, telephone num ber). 
xLot number(s). 
xUnique Subject Identifier(s). 
xIndication of who first observed c omplaint (site personnel or s ubject). 
xOD/OS indication, along with wheth er the lens was inserted. 
xAny related AE number if applicable. 
xDetailed complaint description (scheduled/unscheduled visit, we ar time, symptoms, 
resolution of symptoms, etc.). 
xEye Care Provider objective (slit lamp) findings if applicable.  
xConfirmation of product availability for return (and tracking i nformation, if available), 
or rationale if product is not available for return (
for test article r eturn instructions).
Once a complaint is received, it will be assessed by the COM, C RA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (A E/SAE). If the complaint 
CR-6372, v 2.0  
 
Page 66 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
results in an AE/SAE, the COM/CRA, or trained site personnel wi ll follow Section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these 
procedures also applies and w ill be executed in parallel.   
In some cases, a PQC form may be generated in EDC by the site i n error. In this event, the 
PQC forms will be marked “Intentionally Left Blank” or “ILB”.  Justification for ILB must be 
documented. 
13. ADVERSE EVENTS
13.1. Definitions and Classifications
Adverse Event (AE) – An AE is “any untoward medical  occurrence, unintended disease or 
injury, or untoward clinical signs  (including abnormal laborato ry findings) in subjects, users 
or other persons, whether or not r elated to the investigational  medical device.  
This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. Fo r users or other persons, this definition is 
restricted to events related to  investigational medical devices1
An AE includes any condition (including a pre-existing conditio n) that: 
1. Was not present prior to the study, but appeared or reappeare d following initiation of 
the study. 
2. Was present prior to the stu dy, but worsened during the study . This would include any 
condition resulting from concomita nt illnesses, reactions to co ncomitant medications, 
or progression of disease states. 
3. Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the eve nt. 
Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following: 
xDeath
xSerious deterioration in the hea lth of the subject that resulte d in any of the following: 
xLife-threatening illness or injury
xPermanent or persistent impairm ent of a body structure or a bod y function 
xHospitalization or prolongati on of patient hospitalization
xMedical or surgical intervention to prevent life-threatening il lness or injury or 
permanent impairment to a body structure or a body function. 
xChronic disease
xFetal distress, fetal death or a congenital physical or mental im pairment of birth defect.
Diagnoses and conditions that are considered Ocular Serious Adv erse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle corrected visual acuity eq uivalent to 2 acuity lines 
or greater
CR-6372, v 2.0  
 
Page 67 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis 
xHypopyon 
xHyphemia
xPenetration of Bow man’s Membrane 
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events  – are defined as events that are symptomatic and warrant 
discontinuation (temporary or perm anent) of the contact lens we ar 
Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but 
not limited to the following:
xContact Lens Induced Per ipheral Ulcer (CLPU) 
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesions (SEALs)
xAny Temporary Loss of >2 Lines of BSCVA
xOther Grade 3 or higher corneal f indings, such as abrasions or edema 
xNon-contact lens related corneal  events - e.g. Epidemic Keratoc onjunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinua tion >2 weeks
Non-Significant Adverse Events  – are defined as those events tha t are usually asymptomatic 
and usually do not warrant disc ontinuation of contact lens wear  but may cause a reduction in 
wear time.  However, the Investigator may choose to prescribe t reatment as a precautionary 
measure.   
Diagnoses and conditions that are considered Ocular Non-Signifi cant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or signific ant adverse event, which 
necessitates temporary le ns discontinuation < 2 weeks 
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.
CR-6372, v 2.0  
 
Page 68 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
concomitant treatment of concomitant disease(s). The relationsh ip in time is very 
suggestive, e.g. it is confirmed b y de-challenge and re-challen ge. 
13.2.2. Severity Assessment
Severity Assessment – A qualitative assessment of the degree of intensity of an adve rse event 
as determined by the Investigator or reported to him/her by the  subject. The assessment of 
severity is made irrespective of test article, study treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to t he following scale: 
xMild – Event is noticeable to the subject, but is easily tolerat ed and does not interfere 
with the subject’s daily activities.
xModerate – Event is bothersome, possible requiring additional th erapy, and may 
interfere with the subject’s daily activities.
xSevere – Event is intolerable, n ecessitates additional therapy o r alteration of therapy 
and interferes with the s ubject’s daily activities. 
13.3. Documentation and Follow-Up of Adverse Events
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or st udy procedure.  Adverse events 
reported before the use of test article, start of study treatme nt, or study procedures will be 
recorded as medical history. However, if the condition deterior ates at any time during the study 
it will be recorded and reported as an AE. Untoward medical eve nts reported after the subject’s 
exit from the study will be recorded as adverse events at the d iscretion of the Investigator.
Upon finding an adverse event, the Principal Investigator will document the condition in the 
subject record and in the eCRFs. He/she will complete the Adver se Event /eCRF.  
Complete descriptions of all adverse events must be available i n the subject record. All 
Adverse Events including local a nd systemic reactions not meeti ng the criteria for “serious 
adverse events” shall be captured on the appropriate case report form or electronic data system. 
All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.   
It is the Investigator’s responsibility to maintain documentati on of each reported adverse event. 
All adverse events will be followed in accordance with applicab le licensing requirements. Such 
documentation will include the following: 
xAdverse event (diagnosis not symptom). 
xDrawings or photographs (where appropriate) that detail the fin ding (e.g., size,
location, and depth, etc.). 
xDate the clinical  site was notified.
xDate and time of onset.
xDate and time of resolution.
xAdverse event classification, s everity, and relationship to tes t articles, as applicable. 
xTreatment regimen instituted, including concomitant medications  prescribed, in 
accordance with applicable licensing requirements.
CR-6372, v 2.0  
 
Page 70 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xAny referral to another health care provider if needed.
xOutcome, ocular damage (if any). 
xLikely etiology. 
xBest corrected visual acuity at the discovery of the event and upon conclusion of the 
event. 
In addition, if an infiltrate(s) is present, he/she will comple te the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the  date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be documented to allow a n assessment of the duration 
o f  t h e  e v e n t  a t  e a c h  l e v e l  o f  i n t e n s i t y  t o  b e  p e r f o r m e d .  A d v e r s e events characterized as 
intermittent require documentation of the onset and duration of  each episode. Changes in the 
assessment of relationship to t he Test Article shall also be cl early documented.
Subjects who present with an adverse event shall be followed by  the Investigator, within 
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatment beyond licen sure is required, the patient will 
be referred to the appropriate health care provider. The Invest igator will use his/her clinical 
judgment as to whether a subject  reporting with an adverse even t will continue in the study. If 
a subject is discontinued from th e study, it will be the respon sibility of the Investigator to 
record the reason for discontinuation. The Investigator will al so document the adverse event 
appropriately and complete the A dverse Event eCRF. Any subjects  with ongoing adverse 
events related to the test artic le, study treatment or study pr ocedures, as of the final study visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by the Investigator. Non-o cular adverse events that are 
not related to the test article, study treatment, or study procedures may be recorded as “ongoing” without further follow-up. 
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an adverse event by  e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery f or any serious /significant 
adverse events, and 2 days from discovery for any non-significa nt adverse event. In addition, 
a written report will be submitted by the Principal Investigato r to the IEC/IRB according to 
their requirements (Section 13.4.2) . The report will comment wh ether the adverse event was 
considered to be related to the test article, stu dy treatment o r study procedures.
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/signifi cant adverse events occurring 
during the study period as soon as possible by e-mail, fax, or telephone, but no later than 24 
hours following discovery of the event. The Investigator is obl igated to pursue and obtain 
information requested by the S ponsor in addition to that information reported on the eCRF. All 
CR-6372, v 2.0  
 
Page 71 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
subjects experiencing a serious/s ignificant adverse event must be followed up and all outcomes 
must be reported. 
When medically necessary, the Investigator may break the random ization code to determine 
the identity of the treatment that the subject received. The Sp onsor and study monitor should 
be notified prior to unmasking the test articles.In the event of a serious/significant adverse event, the Invest igator must: 
xNotify the Sponsor immediately. 
xObtain and maintain in the subject’s records all pertinent medi cal information and 
medical judgment for colleagues who assisted in the treatment an d follow-up of the 
subject.
xProvide the Sponsor with a complete case history which includes  a statement as to 
whether the event was or was not  related to the use of the test  article. 
xNotify the IEC/IRB as required by the IEC/IRB reporting procedu re according to 
national regulations. 
Unanticipated (Serious) A dverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effec t (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than 24 hours after the Investigator first learns of the effect . This report is in addition to the 
immediate notification mentioned above.The Sponsor must conduct an evalu ation of the UADE and must rep ort the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after 
the Sponsor first receives  notification of the effect. 
Non-Serious Adverse Events
All non-serious adverse events, including non-serious adverse d evice effects, will be reported 
to the sponsor by the Investigator no later than 2 days from di scovery. 
13.4.2. Reporting Adverse Events to t he Responsible IEC/IRB and Health Authorities
Adverse events that meet the IEC /IRB requirements for reporting  must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by their Approving IEC/IRB. Each clinical site will refer to an d follow any guidelines set forth 
by their local governing Health Authorities.
The Sponsor will report applicable  Adverse Events to the local health authorities according the 
written guidelines, including reporting timelines. 
13.4.3. Event of Special Interest
None 
CR-6372, v 2.0  
 
Page 72 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.5. Reporting of Pregnancy 
Subjects reporting pregnancy (by self-report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregn ant participants and their 
fetuses will not be monitored for study related purposes. At th e Investigator’s discretion, the 
study participant may be followed by the Investigator through d elivery. However, this data will 
not be collected as part of the clinical study database. Pregna nt participants are not 
discontinued from contact lens or  solution related studies for safety concerns, but due to 
general concerns relating to pre gnancy and contact lens use. Sp ecifically, pregnant women are 
discontinued due to fluctuations  in refractive error and/or vis ual acuity that occur secondary to 
systemic hormonal changes, a nd not due to unforeseen health risks to the mother or fetus. 
14. STATISTICAL METHODS
14.1. General Considerations
All data summaries and statistical analyses will be performed u sing the SAS software version 
9.4 (SAS Institute, Cary, NC). Throughout the analysis of data,  the results for each subject/eye 
will be used when available for summarization and statistical a nalysis.  Unscheduled visits will 
be summarized separately and w ill be excluded from the statistic al analysis.
Summary tables (Descriptive statistics and/or frequency tables)  will be provided by lens type 
for all baseline variables, efficacy variables and safety varia bles as appropriate. Continuous 
variables will be summarized with descriptive statistics (n, me an, standard deviation [SD],
median, minimum and maximum). Fre quency count and percentage of  subjects or eyes within 
each category will be provided for categorical data.
14.2. Sample Size Justification
The study was powered to demonstrate non-inferiority of the Test lens relative to the Control 
with respect to binocular visual performance with minimum of 90 % power and two-sided type 
I error of 5%.   Assuming no differe nce between Test and Contro l, the required sample size to 
achieve non-inferiority for dista nce, intermediate and near vis ual performance at different 
lighting conditions are summarized in Table 5. The intra-class correlation (ICC) and standard 
deviations (STD) used in the sam ple size calculations were from a similar study (CR6267).
The sample size calculations wer e conducted using the SAS proce dure PROC POWER for 
paired t-test.
Table 5: Required sample t o achieve non-inferiority
Distance Lighting ConditionSTD
TestSTD 
Control ICCSample 
Size 
DistanceHigh Luminance High Contrast 0.091 0.094 0.60 31
High Luminance Low Contrast 0.091 0.105 0.68 29
Low Luminance High Contrast 
with Distance Goggles0.101 0.092 0.64 31
CR-6372, v 2.0  
 
Page 73 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
IntermediateHigh Luminance High Contrast 0.095 0.116 0.68 34
High Luminance Low Contrast 0.107 0.129 0.71 38
Low Luminance High Contrast 
with Near Goggles0.125 0.152 0.81 36
NearHigh Luminance High Contrast 0.086 0.113 0.63 36
High Luminance Low Contrast 0.103 0.130 0.69 40
Low Luminance High Contrast 
with Near Goggles0.115 0.137 0.73 40
STD: standard deviation, ICC: intra-class correlation
After adjusting for 7% drop-outs or lost to follow-up, the plan  is to enroll 48 subjects with a 
target completion of 40 subjects.  
14.3. Analysis Populations 
The following analysis populations will be defined and used in t he analysis and presentation 
of the data.  
 
All Enrolled:  
All Enrolled Population includes all subjects with recorded dat a in the electronic Case Report 
Form (eCRF) database  
 
Intent-To-Treat (ITT):  
Intent-to-treat will include all the subjects who were randomiz ed to study treatment. Subjects 
will be analyzed as per randomiz ed treatment. At least one obser vation should be 
recorded. Discontinued subjects,  subjects with major protocol de viations and ineligible 
subjects who were inadvertentl y randomized will  be included in the ITT analyses.  
 
Safety Population:  
All subjects who were administered any test article excluding s ubjects who drop out prior to 
administering any test article. At least one observation for sa fety endpoints should be recorded 
(e.g. ocular symptom, slit-lamp finding, etc.) or on after trea tment start date. Subjects will be 
analyzed as per treatment received.  
 
Per Protocol (PP)  
All subjects who have successful ly completed the study and did not substantially deviate from 
the protocol as determined by the trial cohort review committee  prior to database hard lock. 
Justification of excluding subjects with protocol deviations fr om the per-protocol population 
set will be documente d in a memo to file.
The primary analysis will be c onducted on the per-protocol popu lation. A sensitivity analysis 
will be conducted on the ITT population.  
CR-6372, v 2.0  
 
Page 74 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.4. Level of Statistical Significance
All planned analysis for this  study will be conducted with an o verall type I error rate of 5%.  
14.5. Primary Analysis  
Visual Performance:
Binocular visual performance at 2-week follow-up visit will be analyzed separately by lighting 
condition and distance using a Bayesian repeated measurement ra ndom-effects model to 
compare between Test and Control lenses.  Each regression model  will include baseline values, 
lens type, lens wearing sequenc e and lens wearing period as fix ed effects and investigational 
site as random effect.  Other subject characteristics such as a ge, gender will be included as 
fixed effects when appropriate.  U nstructured covariance matrix  will be used to model the 
residual errors among observations within subjects.  Non inform ative prior distributions will 
be used for the coefficients in the models as well as for the error terms.  Independent vague 
normal N(0,1000) priors w ill be used for the regression coeffic ients, inverse gamma IG(0.001, 
0.001) for the variance of the random effect site and inverse W ishart for the residual errors.  A 
Markov-Chain Monte Carlo (MCMC) s ampling algorithm will be used  to carry out the 
marginal posterior distributions of the parameters.  Results wi ll be reported as regression 
coefficient mean estimates with 95% credible intervals.
 The null and alternative hypothe ses for non-inferiority of Tes t lens relative to Control are as
follows: 
ܪ0: ǻ!
ܣܪ:ǻ
ZKHUHǻLVWKHSRVWHULRUPHDQGLIIHUHQFHLQYLVXDOSHUIRUPDQFH EHWZHHQ7HVWDQG&RQWURO7HVW
minus Control).  Non-inferiority will be declared if the upper bound of the credible interval of 
the posterior mean difference is less than 0.05.   
The primary analysis will be c onducted on the per-protocol popu lation. A sensitivity analysis 
will be conducted on the ITT population. 
14.6. Secondary Analysis 
All secondary endpoints will be s ummarized with descriptive stat istics at baseline and follow-
up visits for each study lens ty pe. Safety variables will be su mmarized on safety population 
and efficacy variables on both pe r-protocol and ITT populations.  
14.7. Other Exploratory Analyses  
Comfort and Vision CLUE Scores
CLUE comfort and vision CLUE scores will be analyzed separately  using the same statistical 
PHWKRGGHVFULEHGLQWKHSULPDU\D QDO\VLV3RVWHULRUPHDQGLIIHU HQFHVįLQ&/8(VFRUHV
between Test and Control will be calculated with 95% credible i ntervals. The probability of 
achieving non-inferiority using a margin of -5 point in the CLU E scale,3Uį -5 | data), will 
be calculated.
CR-6372, v 2.0  
 
Page 75 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Further exploratory analysis will be conducted if necessary, at  the discretion of the Study 
Responsible Clinician. 
14.8. Interim Analysis
No interim analysis is planned in this study
14.9. Procedure for Handling Missing Data and Drop-Outs
Missing or spurious values will not be imputed. The count of mi ssing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be  one of the main reasons of mi ssing data in this clinical trial. 
Past clinical trials don’t provide  the evidence that subject dr opout is systematic or not-at-
random. To evaluate the impact of missing data, sensitivity ana lysis may be conducted using 
multiple imputation methods. The S AS/STAT procedures PROC MI and  PROC 
MIANALYZE will be utilized with a parametric regression method used to make at least 20 
imputations.
14.10. Procedure for Reporting Devia tions from Statistical Plan
The analysis will be conducted according to that specified in a bove sections. There are no 
known reasons for which it is planned to deviate from these ana lysis methods. If for any reason 
a change is made, the change w ill be documented in the study re port along with a justification 
for the change.
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING
15.1. Electronic Case Report Form/Data Collection
The data for this study will be captured on electronic case rep ort forms (eCRFs) using an EDC 
system EDC system (Bioclinica). An authorized data originator w ill enter study data into the 
eCRFs using the EDC system. Data collected on equipment that is  not captured in EDC will 
be formatted to the specification of the JJVC  database manager and sent to JJVC for analysis.  
External Data Sources for this study include: Not Applicable
The clinical data will be recorded on dedicated eCRFs specifica lly designed to match the study 
procedures for each visit. Only specifically delegated staff ca n enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and complete ness and signed by the 
Investigator. The sponsor or sponsor’s representatives will be authorized to gain access to the 
subject recordation for the pur poses of monitoring and auditing  the study.  
Edit checks, electronic queries, and audit trails are built int o the system to ensure accurate and 
complete data collection. Data  will be transmitted from the cli nical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigato r will be provided with Individual 
CR-6372, v 2.0  
 
Page 76 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Patient Profiles (IPP) including the full audit trail on electr onic media in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study.  
The content and structure of the  eCRFs are compliant with ISO14 155:2011.1
15.2. Subject Record
At a minimum, subject record shoul d be available for the follow ing: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion 
xprovision of and date of  informed consent 
xvisit dates
xresults of safety and efficacy pa rameters as required by the pr otocol
xa record of all adverse events
xfollow-up of adverse events 
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion 
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. T he first point of entry is consid ered to be the source record. 
Adverse event notes must be rev iewed and initialed by the Inves tigator. 
15 15.3 ClinicalTrials.gov  
This trial will be regis tered on clincaltrials.gov 
16. DATA MANAGEMENT
16.1. Access to Source Data/Document
The Investigator/Institution will permit trial-related monitori ng, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source d ata/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or regula tory authority, JJVC must be 
contacted and notified in w riting within 24 hours. 
16.2. Confidentiality of Information 
Information concerning the inve stigational produc t and patent a pplication processes, scientific 
data or other pertinent information is confidential and remains  t h e  p r o p e r t y  o f  J J V C .  T h e  
CR-6372, v 2.0  
 
Page 77 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Investigator may use this information for the purposes of the s tudy only. It is understood by 
the Investigator that JJVC will use information developed in th is clinical study in connection 
with the development of the inve stigational product and therefo re may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, the Investigator understands that he/she has an 
obligation to provide complete test results and all data develo ped during this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of d ata, include the selection of 
qualified investigators and appr opriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn , must ensure that all Sub-
Investigators and clinical site  personnel are familiar with the  protocol and all study-specific 
procedures and have app ropriate knowledge of the study article.  
Training on case report form completion will be provided to cli nical site personnel before the 
start of the study. The Sponsor will review case report forms f or accuracy and completeness 
remotely during the conduct of t he study, during monitoring vis its, and after transmission to 
data management. Any data discrepancies will be resolved with t he Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regul ations pertaining to the conduct 
of clinical trials. The clinical sites will provide direct acce ss to study-related source 
data/documents and reports for the purpose of monitoring and au diting by JJVC and for 
inspection by local and regulatory authorities. 
17. CLINICAL MONITORING
The study monitors will maintain close contact with the Principa l Investigator and the 
Investigator’s designated clin ical site personnel. The monitor’ s responsibilities will include:
xEnsuring that the investigation is being conducted according to  t h e  p r o t o c o l ,  a n y  
subsequent versions, and regulato ry requirements are maintained . 
xEnsuring the rights and wellbei ng of subjects are protected. 
xEnsuring adequate resources, incl uding facilities, laboratories , equipment, and 
qualified clinical  site personnel.
xEnsuring that protocol deviations are documented with correctiv e action plans, as 
applicable. 
xEnsuring that the clinical site has sufficient test article and  supplies. 
xClarifying questions regarding the study. 
xResolving study issues or problems that may arise. 
xReviewing of study records and source documentation verificatio n in accordance with 
the monitoring plan. 
CR-6372, v 2.0  
 
Page 78 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
18. ETHICAL AND REGULATORY ASPECTS
18.1. Study-Specific Desi gn Considerations
Potential subjects will be fully informed of the risks and requ irements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation. Subject s will be told that their consent to part icipate in the study is voluntary and 
may be withdrawn at any time with  no reason given and without p enalty or loss of benefits to 
which they would otherwise be entitled. Only subjects who are f ully able to understand the 
risks, benefits, and potential adverse events of the study, and  provide their consent voluntarily 
will be enrolled.
18.2. Investigator Responsibility 
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agreement, the investigational plan,  Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP),2and applicable regulatory requirements. GCP is 
an international ethical and scie ntific quality standard for de signing, conducting, recording, 
and reporting studies that invol ve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and  well-being of study subjects are 
protected, consistent with the pr inciples of the Declaration of  Helsinki 64thWMA General 
Assembly 20133and that the clinical study data are credible. The Investigator  must maintain 
clinical study files in accordance with Section 8 of the ICH E6  guidelines on Good Clinical 
Practice (GCP),2 and applicable regulatory requirements. 
18.3. Independent Ethics Committee  or Institutional Review Board  (IEC/IRB)
Before the start of the study, the Investigator (or Sponsor whe n applicable) will provide the 
IEC/IRB with current and compl ete copies of the following docum ents (where applicable): 
xFinal protocol. 
xSponsor-approved informed consent form (and any other written m aterials to be 
provided to the subjects) 
xInvestigator’s Brochure (or equivalent information). 
xSponsor-approved subject recruitment materials. 
xInformation on compensation for study-related injuries or payme nt to subjects for 
participation in the study. 
xInvestigator’s curriculum vit ae, clinical licenses, or equivale nt information (unless not 
required, as documented by IEC/IRB). 
xInformation regarding funding, name of the Sponsor, institutional affiliations, other 
potential conflicts of interest , and incentives for subjects. 
xAny other documents that the IEC/IRB requests to fulfill its obligation.
This study will be undertaken only after IEC/IRB has given full approval of the final protocol,
the informed consent form, applicable recruiting materials, and  subject compensation 
programs, and the Sponsor has received a copy of this approval.  This approval letter must be 
dated and must clearly identify th e documents being approved. 
CR-6372, v 2.0  
 
Page 79 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
During the study, the Investigat or (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for the ir review and approval, where a ppropriate: 
xProtocol revisions 
xRevision(s) to informed consent form and any other written mate rials to be provided to 
subjects
xIf applicable, new or revised s ubject recruitment materials app roved by the Sponsor 
xRevisions to compensation for study-related injuries or payment to subjects for 
participation in the study
xInvestigator’s Brochure revisions  
xSummaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
xReports of adverse events that are serious, unanticipated, and associated with the test 
articles, according to t he IRB’s requirements
xNew information that may adversely affect the safety of the sub jects or the conduct of 
the study 
xMajor protocol deviations a s required by the IEC/IRB 
xReport of deaths of subjects under the Investigator's care 
xNotification if a new Investigat or is responsible for the study  at the clinical site
xAny other requirements of the IEC/IRB 
For protocol revisions that incr ease subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for re view and approval before 
implementation of t he change(s). 
At least once a year, the IEC/IRB will review and reapprove thi s clinical study. This request 
should be documented in writing. 
At the end of the study, the Investigator (or Sponsor where req uired) will notify the IEC/IRB 
about the study completion. Docu mentation of this notification must be retained at the clinical 
site and a copy provided to the  CRO or Sponsor as applicable. 
18.4. Informed Consent
Each subject or their representative, must give written consent  according to local requirements 
after the nature of the study has been fully explained. The con sent form must be signed before 
performance of any study-related activity. The consent form tha t is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. The informed con sent is in accordance with 
principles that originated in the Declaration of Helsinki,3current ICH2and ISO 141551
guidelines, applicable regulat ory requirements, and Sponsor Pol icy. 
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort it may e ntail. Subjects will be informed 
that their participation is volunt ary and that they may withdra w consent to participate at any 
time. 
CR-6372, v 2.0  
 
Page 80 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
The subject will be given sufficient time to read the informed consent form and the opportunity 
to ask questions. After this exp lanation and before entry into the study, consent should be 
appropriately recorded by means of the subject's dated signatur e. After having obtained the 
consent, a copy of the informed consent form must be given to t he subject. 
18.5. Privacy of Personal Data 
The collection, processing and di sclosure of personal data and medical information related to 
the Study Subject, and personal da ta related to Principal Inves tigator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curricu lum vitae) is subject to 
compliance with the Health Information Portability and Accounta bility Act (HIPAA) in the 
United States5and other applicable personal da ta protection and security laws and regulations. 
Appropriate measures will be emplo yed to safeguard these data, to maintain the confidentiality 
of the person’s related health a nd medical information, to prop erly inform the concerned 
persons about the collection and processing of their personal d ata, to grant them reasonable 
access to their personal data a nd to prevent access by unauthor ized persons. 
All information obtained during the course of the investigation  will be regarded as confidential. 
All personal data gathered in this trial will be treated in str ictest confidence by Investigators, 
monitors, Sponsor’s personnel a nd IEC/IRB. No data will be disc l o s e d  t o  a n y  t h i r d  p a r t y  
without the express permission of the subject concerned, with t he exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizati ons in the context of their 
investigation related activities that, as part of the investiga tion will have access to the CRFs 
and subject records. 
The collection and processing o f personal data from subjects en rolled in this study will be 
limited to those data that are necessary to investigate the eff icacy, safety, quality, and utility of 
the investigational product (s) used in this study. 
These data must be collected and processed with adequate precau tions to ensure confidentiality 
and compliance with applicable da ta privacy protection laws and  regulations. 
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully. 
xcollected for specified, explicit, and legitima te purposes and not further processed in a 
way incompatible with these purposes. 
xadequate, relevant , and not excessive i n relation to said purpo ses. 
xaccurate and, where necessary, kept current. 
Explicit consent for the processing of personal data will be ob tained from the participating 
subject before collection of dat a. Such consent should also add ress the transfer of the data to 
other entities and to other countries.The subject has the right to re quest through the Investigator access to his personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
CR-6372, v 2.0  
 
Page 81 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
should be taken to respond to suc h a request, taking into consi deration the nature of the request, 
the conditions of the study, and the applicable laws and regula tions. 
Appropriate technical and organiza tional measures to protect th e personal data against 
unauthorized disclosures or acce ss, accidental or unlawful dest ruction, or accidental loss or 
alteration must be put in place.  Sponsor personnel whose responsibilities require access to 
personal data agree to keep the i dentity of study subjects conf idential. 
19. STUDY RECORD RETENTION
In compliance with the ICH/GCP guidelines,2the Investigator/Institution will maintain all 
CRFs and all subject records tha t support the data collected fr om each subject, as well as all 
study documents as specified in ICH/GCP2and all study documents as specified by the 
applicable regulatory requirement(s). The Investigator/Institut ion will take measures to prevent 
accidental or premature dest ruction of these documents.
Essential documents must be retained until at least two (2) year s after the last approval of a 
marketing application in an ICH region and until there are no p ending or contemplated 
marketing applications in an ICH region or until at least two (2 ) years have elapsed since the 
formal discontinuation of clini cal development of the investiga tional product. These 
documents will be retained for a longer period if required by t he applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibi lity of the Sponsor to inform the 
Investigator/Institution as t o when these documents no longer n eed to be retained. 
If the responsible Investigator r etires, relocates, or for othe r reasons withdraws from the 
responsibility of keeping the study records, custody must be tr ansferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name and address of 
the new custodian. Under no circum stance shall the Investigator relocate or dispose of any 
study documents before having  obtained written approval from th e Sponsor. 
If it becomes necessary for the  Sponsor or the appropriate regu latory authority to review any 
documentation relating to this st udy, the Investigator must per mit access to such reports.  
If the Investigator has a questi on regarding retention of study records, he/she should contact 
JJVC.
20. FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agreement will be signed by the Princip al Investigator and a JJVC 
management representative prior to study initiation.
JJVC reserves the right to w ithhold remunerati on for costs asso ciated with protocol violations 
such as:
xContinuing an ineligible subject in the study. 
xScheduling a study visit outside  the subject’s acceptable visit range. 
CR-6372, v 2.0  
 
Page 82 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
JJVC reserves the right to wit hhold final remuneration until al l study related activities have 
been completed, such as:
xQuery resolution. 
xCase Report Form signature. 
xCompletion of any fo llow-up action items. 
21. PUBLICATION
This study will be registered on C linicalTrials.gov by the Spon sor. 
22. REFERENCES
1. ISO 14155:2011: Clinical Investig ation of Medical Devices for  Human Subjects — 
Good Clinical Practice. Available at: https://www.iso.org/stand ard/45557.html  
2. International Conference on Harmonization Good Clinical Pract ice E6 (ICH-GCP). 
Available at: http://www.ich.org/ products/guidelines/efficacy/a rticle/efficacy-
guidelines.html  
3. Declaration of Helsinki - Ethi cal principles for  Medical Rese arch Involving Human 
Subjects. Available at: https ://www.wma.net/po licies-post/wma-d eclaration-of-
helsinki-ethical-principles-for-m edical-research-involving-huma n-subjects/  
4. United States (US) Code of Fede ral Regulations (CFR). Availab le at: 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectio nCode=CFR  
5. Health Information Portabilit y and Accountability Act (HIPAA) . Available at: 
https://www.hhs.gov/hipaa/for-pro fessionals/privacy/index.html  
6. EU MDR 2017/745 
7. Wirth, R.J., et al., Development  of the Contact Lens User Exp erience: CLUE Scales. 
Optom Vis Sci, 2016. 93(8): p. 801-8. 
CR-6372, v 2.0  
 
Page 83 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)
CR-6372, v 2.0  
 
Page 84 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6372, v 2.0  
 
Page 85 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6372, v 2.0  
 
Page 86 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6372, v 2.0  
 
Page 87 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6372, v 2.0  
 
Page 88 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6372, v 2.0  
 
Page 89 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6372, v 2.0  
 
Page 90 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6372, v 2.0  
 
Page 91 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6372, v 2.0  
 
Page 92 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6372, v 2.0  
 
Page 93 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6372, v 2.0  
 
Page 94 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
CR-6372, v 2.0  
 
Page 95 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
CR-6372, v 2.0  
 
Page 96 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
CR-6372, v 2.0  
 
Page 97 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
CR-6372, v 2.0  
 
Page 98 of 225JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
CR-6372, v 2.0  
 
Page 99 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
CR-6372, v 2.0  
 
Page 100 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
CR-6372, v 2.0  
 
Page 101 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
CR-6372, v 2.0  
 
Page 102 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 19
CR-6372, v 2.0  
 
Page 103 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 20
CR-6372, v 2.0  
 
Page 104 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 21
CR-6372, v 2.0  
 
Page 105 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 22
CR-6372, v 2.0  
 
Page 106 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 23
CR-6372, v 2.0  
 
Page 107 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 24
CR-6372, v 2.0  
 
Page 108 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 25
CR-6372, v 2.0  
 
Page 109 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 26
CR-6372, v 2.0  
 
Page 110 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 27
CR-6372, v 2.0  
 
Page 111 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 28
CR-6372, v 2.0  
 
Page 112 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 29
CR-6372, v 2.0  
 
Page 113 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 30
CR-6372, v 2.0  
 
Page 114 of 225JVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 31
CR-6372, v 2.0  
 
Page 115 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE (TO BE PROVIDED 
SEPARATELY)
CR-6372, v 2.0  
 
Page 116 of 225JVC CONFIDENTIAL
T h e  l e n s e s  a r e  t i n t e d  b l u e  u s i n g  R e a c t i v e  B l u e  D y e  # 4  t o  m a k e  t h e  l e n s e s  m o r e  
v i s i b l e  f o r  h a n d l i n g .  A  b e n z o t r i a z o l e  U V  a b s o r b i n g  m o n om e r  i s  u s e d  t o  b l o c k  U V  
r a d i a t i o n .  
L e n s  P r o p e r t i e s : 
T h e  p h y s i c a l / o p t i c a l  p r o p e r t i e s  o f  t h e  l e n s  a r e : 
•  S p e c i ﬁ  c  G r a v i t y  ( c a l c u l a t e d ) :   0 . 9 8  –  1 . 1 2 
•  R e f r a c t i v e  I n d e x :  1 . 4 0 
•  L i g h t  T r a n sm i t t a n c e : 8 5%  m i n im um 
•  S u r f a c e  C h a r a c t e r : H y d r o p h i l i c 
•  W a t e r  C o n t e n t : 5 8% 
•  O x y g e n  P e rm e a b i l i t y  ( D / k ) : 
V A L U E M E T HO D 
2 1 . 4  x  1 0 1 1  ( c m 2/ s e c ) 
( m l  O 2/ m l  x  m m  H g )  @  3 5 ° C   F a t t  ( b o u n d a r y  c o r r e c t e d ,  e d g e  c o r r e c t e d ) 
2 8 . 0  x  1 0 1 1  ( c m 2/ s e c ) 
( m l  O 2/ m l  x  m m  H g )  @  3 5 ° C F a t t  ( b o u n d a r y  c o r r e c t e d ,  n o n - e d g e  c o r r e c t e d ) 
L e n s  P a r am e t e r s  R a n g e s : 
•  D i am e t e r  ( D I A ) : 1 2 . 0  mm  t o  1 5 . 0  mm 
•  C e n t e r  T h i c k n e s s : Va r i e s  w i t h  p o w e r 
•  B a s e  C u r v e  ( B C ) : 7 . 8 5  mm  t o  1 0 . 0 0  mm 
•  S p h e r i c a l  P o w e r  ( D ) : - 2 0 . 0 0 D  t o  + 2 0 . 0 0 D 
•  C y l i n d e r  P o w e r  ( C Y L ) :  - 0 . 2 5 D  t o  - 1 0 . 0 0 D 
•  A x i s  ( A X I S ) : 2 . 5 °  t o  1 8 0 ° 
•  A D D  P o w e r s : + 0 . 2 5 D  t o  + 4 . 0 0 D 
A V A I L A B L E  L E N S  P A R AM E T E R S 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  a r e  h em i s p h e r i c a l  s h e l l s  o f  t h e  
f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 2  mm 
C e n t e r  T h i c k n e s s : 0 . 0 8 4  mm  t o  0 . 2 3 0  mm  ( v a r i e s  w i t h  p o w e r ) 
3
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 1 9  o f  2 2 5 J V C  CO N F I D E N T I A L 
B a s e  C u r v e  ( B C ) : 8 . 5  mm ,  9 . 0  mm 
P ow e r s  ( D ) : - 0 . 5 0 D  t o  - 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
- 6 . 5 0 D  t o  - 1 2 . 0 0 D  ( i n  0 . 5 0 D  i n c r em e n t s ) 
+ 0 . 5 0 D  t o  + 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  f o r  A S T I GM A T I SM  a r e  h em i t o r i c  
s h e l l s  o f  t h e  f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 5  mm 
C e n t e r  T h i c k n e s s : 0 . 0 9 0  mm  t o  0 . 1 8 9  mm  ( v a r i e s  w i t h  p o w e r ) 
B a s e  C u r v e  ( B C ) : 8 . 5  mm 
P ow e r s  ( D ) : + 0 . 0 0  t o  - 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D ,  - 2 . 2 5 D * 
A x i s  ( A X I S ) :  1 0 °  t o  1 8 0 °  i n  1 0 °  i n c r em e n t s 
* - 2 . 2 5 D  c y l i n d e r  i s  a v a i l a b l e  i n  1 0 ° ,  2 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  
1 0 0 ° ,  1 1 0 ° ,  1 6 0 ° ,  1 7 0 ° ,  1 8 0 °  a x e s  o n l y 
- 6 . 5 0 D  t o  - 9 . 0 0 D  ( i n  0 . 5 0 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D ,  - 2 . 2 5 D * 
A x i s  ( A X I S ) :  1 0 ° ,  2 0 ° ,  6 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  1 0 0 ° ,  1 1 0 ° ,  
1 2 0 ° ,  1 6 0 ° ,  1 7 0 ° ,  1 8 0 ° 
* - 2 . 2 5 D  c y l i n d e r  i s  a v a i l a b l e  i n  2 0 ° ,  9 0 ° ,  1 6 0 ° ,  1 8 0 °  
a x e s  o n l y 
+ 0 . 2 5 D  t o  + 4 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D 
A x i s  ( A X I S ) :  1 0 ° ,  2 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  1 0 0 ° ,  1 1 0 ° ,  1 6 0 ° ,  
1 7 0 ° ,  1 8 0 ° 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  M U L T I F O C A L  C o n t a c t  L e n s e s  a r e  h em i s p h e r i c a l  
s h e l l s  o f  t h e  f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 3  mm 
C e n t e r  T h i c k n e s s : 0 . 0 8 4  mm  t o  0 . 2 0 7  mm  ( v a r i e s  w i t h  p o w e r ) 
B a s e  C u r v e  ( B C ) : 8 . 4  mm 
P ow e r s  ( D ) : + 6 . 0 0 D  t o  - 9 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
N e a r  A D D  P ow e r s  
(M A X  A D D ) : L o w  N e a r  A D D  ( L OW ) :  + 1 . 2 5 D 
M e d i um  N e a r  A D D  (M I D ) :  + 1 . 7 5 D 
H i g h  N e a r  A D D  ( H G H ) :  + 2 . 5 0 D 
4
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 0  o f  2 2 5 J V C  CO N F I D E N T I A L 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  ( e t a ﬁ  l c o n  A )  V i s i b i l i t y  T i n t e d  w i t h  
U V  B l o c k e r  v s .  2 4  y r .  o l d  h um a n  c o r n e a  a n d  2 5  y r .  o l d  h um a n  c r y s t a l l i n e  l e n s .  
* T h e  d a t a  a r e  r e p r e s e n t a t i v e  m e a s u r e m e n t s  t a k e n  t h r o u g h  t h e  c e n t r a l  3 - 5  m m  p o r t i o n  f o r  t h e  
t h i n n e s t  m a r k e t e d  l e n s  ( - 3 . 0 0 D  l e n s ,  0 . 0 8 4  m m  c e n t e r  t h i c k n e s s ) . 
1 L e rm a n ,  S . ,  R a d i a n t  E n e r g y  a n d  t h e  E y e ,  M a cM i l l a n ,  N e w  Y o r k ,  1 9 8 0 ,  p .  5 8 ,  ﬁ  g u r e  2 - 2 1 
2 W a x l e r ,  M . ,  H i t c h i n s ,  V .M . ,  O p t i c a l  R a d i a t i o n  a n d  V i s u a l  H e a  t h ,  C R C  P r e s s ,  B o c a  R a t o n ,  F l o r i d a ,  
1 9 8 6 ,  p .  1 9 ,  ﬁ  g u r e  5 
W A R N I N G :  U V  a b s o r b i n g  c o n t a c t  l e n s e s  a r e  NO T  s u b s t i t u t e s  f o r  
p r o t e c t i v e  U V  a b s o r b i n g  e y ew e a r ,  s u c h  a s  U V  a b s o r b i n g  g o g g l e s  
o r  s u n g l a s s e s  b e c a u s e  t h e y  d o  n o t  c om p l e t e l y  c o v e r  t h e  e y e  a n d  
s u r r o u n d i n g  a r e a .  T h e  p a t i e n t  s h o u l d  c o n t i n u e  t o  u s e  U V  a b s o r b i n g  
e y ew e a r  a s  d i r e c t e d . 
A C T IO N S 
I n  i t s  h y d r a t e d  s t a t e ,  t h e  c o n t a c t  l e n s ,  w h e n  p l a c e d  o n  t h e  c o r n e a ,  a c t s  a s  a  
r e f r a c t i n g  m e d i um  t o  f o c u s  l i g h t  r a y s  o n  t h e  r e t i n a . 
T h e  U V  B l o c k i n g  f o r  t h e s e  l e n s e s  a v e r a g e s  9 7%  i n  t h e  U V B  r a n g e  o f  2 8 0  nm  t o  
3 1 5  nm  a n d  8 2%  i n  t h e  U V A  r a n g e  o f  3 1 6  nm  t o  3 8 0  nm  f o r  t h e  e n t i r e  p o w e r  
r a n g e . T R A N SM I T T A N C E  C U R V E S 
1 - D A Y  A C U V U E ® M O I S T 
B r a n d  C o n t a c t  L e n s e s * 
2 4  Y R .  O L D  H U M A N  
C O R N E A 1
2 5  Y R .  O L D  H U M A N 
C R Y S T A L L I N E  L E N S 2
5
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 1  o f  2 2 5 J V C  CO N F I D E N T I A L 
NO T E :  L o n g - t e rm  e x p o s u r e  t o  U V  r a d i a t i o n  i s  o n e  o f  t h e  r i s k  f a c t o r s  
a s s o c i a t e d  w i t h  c a t a r a c t s .  E x p o s u r e  i s  b a s e d  o n  a  n um b e r  o f  f a c t o r s  
s u c h  a s  e n v i r o nm e n t a l  c o n d i t i o n s  ( a l t i t u d e ,  g e o g r a p h y ,  c l o u d  c o v e r )  a n d  
p e r s o n a l  f a c t o r s  ( e x t e n t  a n d  n a t u r e  o f  o u t d o o r  a c t i v i t i e s ) .  U V - B l o c k i n g  
c o n t a c t  l e n s e s  h e l p  p r o v i d e  p r o t e c t i o n  a g a i n s t  h a rm f u l  U V  r a d i a t i o n .  
H ow e v e r ,  c l i n i c a l  s t u d i e s  h a v e  n o t  b e e n  d o n e  t o  d em o n s t r a t e  t h a t  
w e a r i n g  U V - B l o c k i n g  c o n t a c t  l e n s e s  r e d u c e s  t h e  r i s k  o f  d e v e l o p i n g  
c a t a r a c t s  o r  o t h e r  e y e  d i s o r d e r s .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  b e  
c o n s u l t e d  f o r  m o r e  i n f o rm a t i o n . 
I N D I C A T IO N S  ( U S E S ) 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  a r e  i n d i c a t e d  f o r  d a i l y  
d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  r e f r a c t i v e  am e t r o p i a  (m y o p i a  a n d  
h y p e r o p i a )  i n  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  h a v e  
1 . 0 0 D  o r  l e s s  o f  a s t i gm a t i sm . 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  f o r  A S T I GM A T I SM  a r e  i n d i c a t e d  
f o r  d a i l y  d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  r e f r a c t i v e  am e t r o p i a  (m y o p i a  
a n d  h y p e r o p i a )  i n  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  
h a v e  0 . 5 0 D  t o  3 . 0 0 D  o f  a s t i gm a t i sm . 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  M U L T I F O C A L  C o n t a c t  L e n s e s  a r e  i n d i c a t e d  
f o r  d a i l y  d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  d i s t a n c e  a n d  n e a r  v i s i o n  i n  
p r e s b y o p i c  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  h a v e  
4 . 0 0 D  o f  A D D  p o w e r  o r  l e s s  a n d  0 . 7 5 D  o r  l e s s  o f  a s t i gm a t i sm . 
T h e  l e n s e s  c o n t a i n  a  U V  B l o c k e r  t o  h e l p  p r o t e c t  a g a i n s t  t r a n sm i s s i o n  o f  h a rm f u l  
U V  r a d i a t i o n  t o  t h e  c o r n e a  a n d  i n t o  t h e  e y e . 
W h e n  p r e s c r i b e d  f o r  d a i l y  d i s p o s a b l e  u s e ,  n o  c l e a n i n g  o r  d i s i n f e c t i o n  i s  r e q u i r e d .  
L e n s e s  s h o u l d  b e  d i s c a r d e d  u p o n  r em o v a l . 
CO N T R A I N D I C A T IO N S  ( R E A SO N S  NO T  TO  U S E )  
D O  N O T  U S E  t h e s e  l e n s e s  w h e n  a n y  o f  t h e  f o l l ow i n g  c o n d i t i o n s  e x i s t : 
•   A c u t e  o r  s u b a c u t e  i n ﬂ  amm a t i o n  o r  i n f e c t i o n  o f  t h e  a n t e r i o r  c h am b e r  o f  
t h e  e y e . 
•   A n y  e y e  d i s e a s e ,  i n j u r y ,  o r  a b n o rm a l i t y  t h a t  a f f e c t s  t h e  c o r n e a ,  
c o n j u n c t i v a ,  o r  e y e l i d s . 
•   S e v e r e  i n s u f ﬁ  c i e n c y  o f  l a c r im a l  s e c r e t i o n  ( d r y  e y e ) . 
•   C o r n e a l  h y p o e s t h e s i a  ( r e d u c e d  c o r n e a l  s e n s i t i v i t y ) . 
6
C R - 6 3 7 2 ,  v  2 . 0 )  
 
P a g e  1 2 2  o f  2 2 5 J V C  CO N F I D E N T I A L 
•   A n y  s y s t em i c  d i s e a s e  t h a t  m a y  a f f e c t  t h e  e y e  o r  b e  e x a g g e r a t e d  b y  
w e a r i n g  c o n t a c t  l e n s e s . 
•   A l l e r g i c  r e a c t i o n s  o f  o c u l a r  s u r f a c e s  o r  a d n e x a  t h a t  m a y  b e  i n d u c e d  o r  
e x a g g e r a t e d  b y  w e a r i n g  c o n t a c t  l e n s e s  o r  u s e  o f  c o n t a c t  l e n s  s o l u t i o n s . 
•   O c u l a r  i r r i t a t i o n  d u e  t o  a l l e r g i c  r e a c t i o n s  w h i c h  m a y  b e  c a u s e d  b y  u s e  
o f  c o n t a c t  l e n s  s o l u t i o n s  ( i . e . ,  r e w e t t i n g  d r o p s )  t h a t  c o n t a i n  c h em i c a l s  o r  
p r e s e r v a t i v e s  ( s u c h  a s  m e r c u r y ,  T h im e r o s a l ,  e t c . )  t o  w h i c h  s om e  p e o p l e  
m a y  d e v e l o p  a n  a l l e r g i c  r e s p o n s e . 
•   A n y  a c t i v e  c o r n e a l  i n f e c t i o n  ( b a c t e r i a l ,  f u n g a l ,  p r o t o z o a l ,  o r  v i r a l ) . 
•   I f  e y e s  b e c om e  r e d  o r  i r r i t a t e d . 
W A R N I NG S 
P a t i e n t s  s h o u l d  b e  a d v i s e d  o f  t h e  f o l l ow i n g  w a r n i n g s  p e r t a i n i n g  t o  
c o n t a c t  l e n s  w e a r : 
E Y E  P RO B L EM S ,  I N C L U D I N G  CO R N E A L  U L C E R S ,  C A N  D E V E LO P  
R A P I D L Y  A N D  L E A D  TO  LO S S  O F  V I S IO N .  I F  T H E  P A T I E N T  
E X P E R I E N C E S : 
• E y e D i s c om f o r t , 
• E x c e s s i v e T e a r i n g , 
• V i s i o n C h a n g e s , 
•   L o s s  o f  V i s i o n , 
•   E y e  R e d n e s s ,  o r 
•   O t h e r  E y e  P r o b l em s , 
T H E  P A T I E N T  S HO U L D  B E  I N S T R U C T E D  TO  IMM E D I A T E L Y  
R EMO V E  T H E  L E N S E S  A N D  P ROM P T L Y  CO N T A C T  T H E  E Y E  C A R E  
P RO F E S S IO N A L . 
•   W h e n  p r e s c r i b e d  f o r  d a i l y  w e a r ,  p a t i e n t s  s h o u l d  b e  i n s t r u c t e d  n o t  t o  w e a r  
t h e i r  l e n s e s  w h i l e  s l e e p i n g .  C l i n i c a l  s t u d i e s  h a v e  s h o w n  t h a t  w h e n  l e n s e s  
a r e  w o r n  o v e r n i g h t ,  t h e  r i s k  o f  u l c e r a t i v e  k e r a t i t i s  i s  g r e a t e r  t h a n  am o n g  
t h o s e  w h o  d o  n o t  w e a r  t h em  o v e r n i g h t . 3
•   S t u d i e s  h a v e  s h o w n  t h a t  c o n t a c t  l e n s  w e a r e r s  w h o  a r e  sm o k e r s  h a v e  a  
h i g h e r  i n c i d e n c e  o f  a d v e r s e  r e a c t i o n s  t h a n  n o n sm o k e r s . 
•   P r o b l em s  w i t h  c o n t a c t  l e n s e s  o r  l e n s  c a r e  p r o d u c t s  c o u l d  r e s u l t  i n  
s e r i o u s  i n j u r y  t o  t h e  e y e .  P a t i e n t s  s h o u l d  b e  c a u t i o n e d  t h a t  p r o p e r  u s e  
a n d  c a r e  o f  c o n t a c t  l e n s e s  a n d  l e n s  c a r e  p r o d u c t s  a r e  e s s e n t i a l  f o r  t h e  
s a f e  u s e  o f  t h e s e  p r o d u c t s . 
7
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 3  o f  2 2 5 J V C  CO N F I D E N T I A L 
•   T h e  o v e r a l l  r i s k  o f  u l c e r a t i v e  k e r a t i t i s  m a y  b e  r e d u c e d  b y  c a r e f u l l y  
f o l l o w i n g  d i r e c t i o n s  f o r  l e n s  c a r e . 
3  N e w  E n g l a n d  J o u r n a l  o f  M e d i c i n e ,  S e p t em b e r  2 1 ,  1 9 8 9 ;  3 2 1  ( 1 2 ) ,  p p .  7 7 3 - 7 8 3 
S p e c i ﬁ  c  I n s t r u c t i o n s  f o r  U s e  a n d  W a r n i n g s : 
• W a t e r A c t i v i t y 
I n s t r u c t i o n  f o r  U s e 
D o  n o t  e x p o s e  c o n t a c t  l e n s e s  t o  w a t e r  w h i l e  w e a r i n g  t h em . 
W A R N I N G : 
W a t e r  c a n  h a r b o r  m i c r o o r g a n i sm s  t h a t  c a n  l e a d  t o  s e v e r e  i n f e c t i o n ,  
v i s i o n  l o s s ,  o r  b l i n d n e s s .  I f  l e n s e s  h a v e  b e e n  s u bm e r s e d  i n  w a t e r  w h e n  
p a r t i c i p a t i n g  i n  w a t e r  s p o r t s  o r  s w imm i n g  i n  p o o l s ,  h o t  t u b s ,  l a k e s ,  o r  
o c e a n s ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  d i s c a r d  t h em  a n d  r e p l a c e  
t h em  w i t h  a  n e w  p a i r .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  b e  c o n s u l t e d  f o r  
r e c omm e n d a t i o n s  r e g a r d i n g  w e a r i n g  l e n s e s  d u r i n g  a n y  a c t i v i t y  i n v o l v i n g  
w a t e r . 
P R E C A U T IO N S 
S p e c i a l  P r e c a u t i o n s  f o r  E y e  C a r e  P r o f e s s i o n a l s : 
•   D u e  t o  t h e  sm a l l  n um b e r  o f  p a t i e n t s  e n r o l l e d  i n  c l i n i c a l  i n v e s t i g a t i o n  o f  
l e n s e s ,  a l l  r e f r a c t i v e  p o w e r s ,  d e s i g n  c o n ﬁ  g u r a t i o n s ,  o r  l e n s  p a r am e t e r s  
a v a i l a b l e  i n  t h e  l e n s  m a t e r i a l  a r e  n o t  e v a l u a t e d  i n  s i g n i ﬁ  c a n t  n um b e r s .  
C o n s e q u e n t l y ,  w h e n  s e l e c t i n g  a n  a p p r o p r i a t e  l e n s  d e s i g n  a n d  
p a r am e t e r s ,  t h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  c o n s i d e r  a l l  c h a r a c t e r i s t i c s  
o f  t h e  l e n s  t h a t  c a n  a f f e c t  l e n s  p e r f o rm a n c e  a n d  o c u l a r  h e a l t h ,  i n c l u d i n g  
o x y g e n  p e rm e a b i l i t y ,  w e t t a b i l i t y ,  c e n t r a l  a n d  p e r i p h e r a l  t h i c k n e s s ,  a n d  
o p t i c  z o n e  d i am e t e r . 
T h e  p o t e n t i a l  im p a c t  o f  t h e s e  f a c t o r s  o n  t h e  p a t i e n t ’ s  o c u l a r  h e a l t h  
s h o u l d  b e  c a r e f u l l y  w e i g h e d  a g a i n s t  t h e  p a t i e n t ’ s  n e e d  f o r  r e f r a c t i v e  
c o r r e c t i o n ;  t h e r e f o r e ,  t h e  c o n t i n u i n g  o c u l a r  h e a l t h  o f  t h e  p a t i e n t  a n d  l e n s  
p e r f o rm a n c e  o n  t h e  e y e  s h o u l d  b e  c a r e f u l l y  m o n i t o r e d  b y  t h e  p r e s c r i b i n g  
E y e  C a r e  P r o f e s s i o n a l . 
•   P a t i e n t s  w h o  w e a r  t h e s e  l e n s e s  t o  c o r r e c t  p r e s b y o p i a  u s i n g  m o n o v i s i o n  
( o r  m o d i ﬁ  e d  m o n o v i s i o n  u s i n g  1 - D A Y  A C U V U E ® M O I S T  B r a n d  
M U L T I F O C A L )  m a y  n o t  a c h i e v e  t h e  b e s t  c o r r e c t e d  v i s u a l  a c u i t y  f o r  e i t h e r  
f a r  o r  n e a r  v i s i o n .  V i s u a l  r e q u i r em e n t s  v a r y  w i t h  t h e  i n d i v i d u a l  a n d  s h o u l d  
b e  c o n s i d e r e d  w h e n  s e l e c t i n g  t h e  m o s t  a p p r o p r i a t e  t y p e  o f  l e n s  f o r  e a c h  
p a t i e n t . 
8
C R - 6 3 7 2 ,  v  2 . 0 )  
 
P a g e  1 2 4  o f  2 2 5 J V C  CO N F I D E N T I A L 
•   F l u o r e s c e i n ,  a  y e l l o w  d y e ,  s h o u l d  n o t  b e  u s e d  w h i l e  t h e  l e n s e s  a r e  o n  
t h e  e y e s .  T h e  l e n s e s  a b s o r b  t h i s  d y e  a n d  b e c om e  d i s c o l o r e d .  W h e n e v e r  
ﬂ  u o r e s c e i n  i s  u s e d  i n  e y e s ,  t h e  e y e s  s h o u l d  b e  ﬂ  u s h e d  w i t h  a  s t e r i l e  
s a l i n e  s o l u t i o n  t h a t  i s  r e c omm e n d e d  f o r  i n - e y e  u s e . 
•   E y e  C a r e  P r o f e s s i o n a l s  s h o u l d  i n s t r u c t  t h e  p a t i e n t  t o  r em o v e  l e n s e s  
imm e d i a t e l y  i f  t h e  e y e s  b e c om e  r e d  o r  i r r i t a t e d .  
E y e  C a r e  P r o f e s s i o n a l s  s h o u l d  c a r e f u l l y  i n s t r u c t  p a t i e n t s  a b o u t  t h e  
f o l l ow i n g  c a r e  r e g im e n  a n d  s a f e t y  p r e c a u t i o n s . 
H a n d l i n g  P r e c a u t i o n s : 
•   B e f o r e  l e a v i n g  t h e  E y e  C a r e  P r o f e s s i o n a l ’ s  o f ﬁ  c e ,  t h e  p a t i e n t  s h o u l d  
b e  a b l e  t o  p r om p t l y  r em o v e  t h e  l e n s e s  o r  s h o u l d  h a v e  s om e o n e  e l s e  
a v a i l a b l e  w h o  c a n  r em o v e  t h e  l e n s e s  f o r  h im  o r  h e r . 
•   D O  N O T  u s e  i f  t h e  s t e r i l e  b l i s t e r  p a c k a g e  i s  o p e n e d  o r  d am a g e d . 
•   A l w a y s  w a s h  a n d  r i n s e  h a n d s  b e f o r e  h a n d l i n g  l e n s e s .  D o  n o t  g e t  
c o sm e t i c s ,  l o t i o n s ,  s o a p s ,  c r e am s ,  d e o d o r a n t s ,  o r  s p r a y s  i n  t h e  e y e s  o r  
o n  t h e  l e n s e s .  I t  i s  b e s t  t o  p u t  o n  l e n s e s  b e f o r e  p u t t i n g  o n  m a k e u p . 
•   D O  N O T  t o u c h  c o n t a c t  l e n s e s  w i t h  t h e  ﬁ  n g e r s  o r  h a n d s  i f  t h e  h a n d s  a r e  
n o t  f r e e  o f  f o r e i g n  m a t e r i a l s ,  a s  m i c r o s c o p i c  s c r a t c h e s  o f  t h e  l e n s e s  m a y  
o c c u r ,  c a u s i n g  d i s t o r t e d  v i s i o n  a n d / o r  i n j u r y  t o  t h e  e y e . 
•   C a r e f u l l y  f o l l o w  t h e  h a n d l i n g ,  i n s e r t i o n ,  r em o v a l ,  a n d  w e a r i n g  i n s t r u c t i o n s  
i n  t h e  P a t i e n t  I n s t r u c t i o n  G u i d e  f o r  t h e s e  l e n s e s  a n d  t h o s e  p r e s c r i b e d  b y  
t h e  E y e  C a r e  P r o f e s s i o n a l . 
•   A l w a y s  h a n d l e  l e n s e s  c a r e f u l l y  a n d  a v o i d  d r o p p i n g  t h em . 
•   N e v e r  u s e  t w e e z e r s  o r  o t h e r  t o o l s  t o  r em o v e  l e n s e s  f r om  t h e  l e n s  
c o n t a i n e r .  S l i d e  t h e  l e n s  u p  t h e  s i d e  o f  t h e  b o w l  u n t i l  i t  i s  f r e e  o f  t h e  
c o n t a i n e r . 
•   D o  n o t  t o u c h  t h e  l e n s  w i t h  ﬁ  n g e r n a i l s . 
L e n s  W e a r i n g  P r e c a u t i o n s : 
•   I f  t h e  l e n s  s t i c k s  ( s t o p s  m o v i n g )  o n  t h e  e y e ,  f o l l o w  t h e  r e c omm e n d e d  
d i r e c t i o n s  i n  “ C a r e  f o r  S t i c k i n g  ( N o n -M o v i n g )  L e n s e s . ”  T h e  l e n s  s h o u l d  
m o v e  f r e e l y  o n  t h e  e y e  f o r  t h e  c o n t i n u e d  h e a l t h  o f  t h e  e y e .  I f  n o n - 
m o v em e n t  o f  t h e  l e n s  c o n t i n u e s ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  
imm e d i a t e l y  c o n s u l t  h i s  o r  h e r  E y e  C a r e  P r o f e s s i o n a l . 
•   N e v e r  w e a r  l e n s e s  b e y o n d  t h e  p e r i o d  r e c omm e n d e d  b y  t h e  E y e  C a r e  
P r o f e s s i o n a l . 
9
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 5  o f  2 2 5 J V C  CO N F I D E N T I A L 
•   T h e  p a t i e n t  s h o u l d  b e  a d v i s e d  t o  n e v e r  a l l o w  a n y o n e  e l s e  t o  w e a r  t h e i r  
l e n s e s .  T h e y  h a v e  b e e n  p r e s c r i b e d  t o  ﬁ  t  t h e i r  e y e s  a n d  t o  c o r r e c t  t h e i r  
v i s i o n  t o  t h e  d e g r e e  n e c e s s a r y .  S h a r i n g  l e n s e s  g r e a t l y  i n c r e a s e s  t h e  
c h a n c e  o f  e y e  i n f e c t i o n s . 
•   I f  a e r o s o l  p r o d u c t s ,  s u c h  a s  h a i r s p r a y ,  a r e  u s e d  w h i l e  w e a r i n g  l e n s e s ,  
e x e r c i s e  c a u t i o n  a n d  k e e p  e y e s  c l o s e d  u n t i l  t h e  s p r a y  h a s  s e t t l e d . 
•   A v o i d  a l l  h a rm f u l  o r  i r r i t a t i n g  v a p o r s  a n d  f um e s  w h i l e  w e a r i n g  l e n s e s . 
L e n s  C a r e  P r e c a u t i o n s : 
•   T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  n o  c l e a n i n g  o r  d i s i n f e c t i o n  i s  n e e d e d  
w h e n  l e n s e s  a r e  w o r n  f o r  d a i l y  d i s p o s a b l e  w e a r .  P a t i e n t s  s h o u l d  a l w a y s  
d i s p o s e  o f  l e n s e s  w h e n  r em o v e d  a n d  h a v e  s p a r e  l e n s e s  o r  s p e c t a c l e s  
a v a i l a b l e . 
O t h e r  T o p i c s  t o  D i s c u s s  w i t h  P a t i e n t s : 
•   A l w a y s  c o n t a c t  t h e  E y e  C a r e  P r o f e s s i o n a l  b e f o r e  u s i n g  a n y  m e d i c i n e  i n  
t h e  e y e s . 
•   C e r t a i n  m e d i c a t i o n s ,  s u c h  a s  a n t i h i s t am i n e s ,  d e c o n g e s t a n t s ,  d i u r e t i c s ,  
m u s c l e  r e l a x a n t s ,  t r a n q u i l i z e r s ,  a n d  t h o s e  f o r  m o t i o n  s i c k n e s s  m a y  c a u s e  
d r y n e s s  o f  t h e  e y e ,  i n c r e a s e d  l e n s  a w a r e n e s s ,  o r  b l u r r e d  v i s i o n .  S h o u l d  
s u c h  c o n d i t i o n s  e x i s t ,  p r o p e r  r em e d i a l  m e a s u r e s  s h o u l d  b e  p r e s c r i b e d .  
•   O r a l  c o n t r a c e p t i v e  u s e r s  c o u l d  d e v e l o p  v i s u a l  c h a n g e s  o r  c h a n g e s  i n  
l e n s  t o l e r a n c e  w h e n  u s i n g  c o n t a c t  l e n s e s .  P a t i e n t s  s h o u l d  b e  c a u t i o n e d  
a c c o r d i n g l y . 
•   A s  w i t h  a n y  c o n t a c t  l e n s ,  f o l l o w - u p  v i s i t s  a r e  n e c e s s a r y  t o  a s s u r e  t h e  
c o n t i n u i n g  h e a l t h  o f  t h e  p a t i e n t ’ s  e y e s .  T h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  
a s  t o  a  r e c omm e n d e d  f o l l o w - u p  s c h e d u l e . 
W h o  S h o u l d  K n ow  T h a t  t h e  P a t i e n t  i s  W e a r i n g  C o n t a c t  L e n s e s ? 
•   P a t i e n t s  s h o u l d  i n f o rm  a l l  d o c t o r s  ( H e a l t h  C a r e  P r o f e s s i o n a l s )  a b o u t  
b e i n g  a  c o n t a c t  l e n s  w e a r e r . 
•   P a t i e n t s  s h o u l d  a l w a y s  i n f o rm  t h e i r  em p l o y e r  o f  b e i n g  a  c o n t a c t  l e n s  
w e a r e r .  S om e  j o b s  m a y  r e q u i r e  u s e  o f  e y e  p r o t e c t i o n  e q u i pm e n t  o r  m a y  
r e q u i r e  t h a t  t h e  p a t i e n t  n o t  w e a r  c o n t a c t  l e n s e s . 
1 0 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 6  o f  2 2 5 J V C  CO N F I D E N T I A L 
A D V E R S E  R E A C T IO N S 
T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  t h e  f o l l ow i n g  p r o b l em s  m a y  o c c u r  
w h e n  w e a r i n g  c o n t a c t  l e n s e s : 
•   T h e  e y e  m a y  b u r n ,  s t i n g ,  a n d / o r  i t c h . 
•   T h e r e  m a y  b e  l e s s  c om f o r t  t h a n  w h e n  t h e  l e n s  w a s  ﬁ  r s t  p l a c e d  o n  t h e  
e y e . 
•   T h e r e  m a y  b e  a  f e e l i n g  o f  s om e t h i n g  i n  t h e  e y e  ( f o r e i g n  b o d y ,  s c r a t c h e d  
a r e a ) . 
•   T h e r e  m a y  b e  t h e  p o t e n t i a l  f o r  s om e  t em p o r a r y  im p a i rm e n t  d u e  t o  
p e r i p h e r a l  i n ﬁ  l t r a t e s ,  p e r i p h e r a l  c o r n e a l  u l c e r s ,  o r  c o r n e a l  e r o s i o n .  T h e r e  
m a y  b e  t h e  p o t e n t i a l  f o r  o t h e r  p h y s i o l o g i c a l  o b s e r v a t i o n s ,  s u c h  a s  l o c a l  
o r  g e n e r a l i z e d  e d em a ,  c o r n e a l  n e o v a s c u l a r i z a t i o n ,  c o r n e a l  s t a i n i n g ,  
i n j e c t i o n ,  t a r s a l  a b n o rm a l i t i e s ,  i r i t i s ,  a n d  c o n j u n c t i v i t i s ,  s om e  o f  w h i c h  a r e  
c l i n i c a l l y  a c c e p t a b l e  i n  l o w  am o u n t s . 
•   T h e r e  m a y  b e  e x c e s s i v e  w a t e r i n g ,  u n u s u a l  e y e  s e c r e t i o n s ,  o r  r e d n e s s  
o f  t h e  e y e . 
•   P o o r  v i s u a l  a c u i t y ,  b l u r r e d  v i s i o n ,  r a i n b o w s  o r  h a l o s  a r o u n d  o b j e c t s ,  
p h o t o p h o b i a ,  o r  d r y  e y e s  m a y  a l s o  o c c u r  i f  t h e  l e n s e s  a r e  w o r n  
c o n t i n u o u s l y  o r  f o r  t o o  l o n g  a  t im e . 
T h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  c o n d u c t  a  s im p l e  3 - p a r t  s e l f - e x am i n a t i o n  a t  
l e a s t  o n c e  a  d a y .  T h e y  s h o u l d  a s k  t h em s e l v e s : 
•   H o w  d o  t h e  l e n s e s  f e e l  o n  m y  e y e s ? 
•   H o w  d o  m y  e y e s  l o o k ? 
•   H a v e  I  n o t i c e d  a  c h a n g e  i n  m y  v i s i o n ?  
I f  t h e  p a t i e n t  r e p o r t s  a n y  p r o b l em s ,  h e  o r  s h e  s h o u l d  b e  i n s t r u c t e d  t o  
IMM E D I A T E L Y  R EM O V E  T H E  L E N S .  I f  t h e  p r o b l em  o r  d i s c om f o r t  s t o p s ,  t h e  
p a t i e n t  s h o u l d  d i s c a r d  t h e  l e n s  a n d  p l a c e  a  n e w  f r e s h  l e n s  o n  t h e  e y e . 
I f  a f t e r  i n s e r t i n g  t h e  n e w  l e n s ,  t h e  p r o b l em  c o n t i n u e s ,  t h e  p a t i e n t  s h o u l d  b e  
d i r e c t e d  t o  IMM E D I A T E L Y  R EM O V E  T H E  L E N S  A N D  C O N T A C T  H I S  O R  H E R  
E Y E  C A R E  P R O F E S S I O N A L . 
T h e  p a t i e n t  s h o u l d  b e  a d v i s e d  t h a t  w h e n  a n y  o f  t h e  a b o v e  s ym p t om s  o c c u r ,  
a  s e r i o u s  c o n d i t i o n  s u c h  a s  i n f e c t i o n ,  c o r n e a l  u l c e r ,  n e o v a s c u l a r i z a t i o n ,  o r  i r i t i s  
m a y  b e  p r e s e n t .  H e  o r  s h e  s h o u l d  b e  i n s t r u c t e d  t o  s e e k  imm e d i a t e  p r o f e s s i o n a l  
i d e n t i ﬁ  c a t i o n  o f  t h e  p r o b l em  a n d  p r om p t  t r e a tm e n t  t o  a v o i d  s e r i o u s  e y e  d am a g e . 
1 1 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 7  o f  2 2 5 J V C  CO N F I D E N T I A L 
G E N E R A L  F I T T I NG  G U I D E L I N E S 
A .  P a t i e n t  S e l e c t i o n 
P a t i e n t s  s e l e c t e d  t o  w e a r  t h e s e  l e n s e s  s h o u l d  b e  c h o s e n  b a s e d  o n :  
•  M o t i v a t i o n  t o  w e a r  l e n s e s  
•  A b i l i t y  t o  f o l l o w  i n s t r u c t i o n s  r e g a r d i n g  l e n s  w e a r 
•  G e n e r a l  h e a l t h  
•  A b i l i t y  t o  a d e q u a t e l y  h a n d l e  a n d  c a r e  f o r  t h e  l e n s e s  
•  A b i l i t y  t o  u n d e r s t a n d  t h e  r i s k s  a n d  b e n e ﬁ  t s  o f  l e n s  w e a r 
P a t i e n t s  w h o  d o  n o t  m e e t  t h e  a b o v e  c r i t e r i a  s h o u l d  n o t  b e  p r o v i d e d  w i t h  c o n t a c t  
l e n s e s .  
B .  P r e - ﬁ  t t i n g  E x am i n a t i o n 
I n i t i a l  e v a l u a t i o n  o f  t h e  p a t i e n t  s h o u l d  b e g i n  w i t h  a  t h o r o u g h  c a s e  h i s t o r y  
t o  d e t e rm i n e  i f  t h e r e  a r e  a n y  c o n t r a i n d i c a t i o n s  t o  c o n t a c t  l e n s  w e a r .  D u r i n g  
t h e  c a s e  h i s t o r y ,  t h e  p a t i e n t ’ s  v i s u a l  n e e d s  a n d  e x p e c t a t i o n s  s h o u l d  b e  
d e t e rm i n e d  a s  w e l l  a s  a n  a s s e s sm e n t  o f  t h e i r  o v e r a l l  o c u l a r ,  p h y s i c a l ,  a n d  
m e n t a l  h e a l t h .  
P r e c e d i n g  t h e  i n i t i a l  s e l e c t i o n  o f  t r i a l  c o n t a c t  l e n s e s ,  a  c om p r e h e n s i v e  o c u l a r  
e v a l u a t i o n  s h o u l d  b e  p e r f o rm e d  t h a t  i n c l u d e s ,  b u t  i s  n o t  l im i t e d  t o ,  t h e  
m e a s u r em e n t  o f  d i s t a n c e  a n d  n e a r  v i s u a l  a c u i t y ,  d i s t a n c e  a n d  n e a r  r e f r a c t i v e  
p r e s c r i p t i o n  ( i n c l u d i n g  d e t e rm i n i n g  t h e  p r e f e r r e d  r e a d i n g  d i s t a n c e  f o r  
p r e s b y o p e s ) ,  k e r a t om e t r y ,  a n d  b i om i c r o s c o p i c  e v a l u a t i o n .  
B a s e d  o n  t h i s  e v a l u a t i o n ,  i f  i t  i s  d e t e rm i n e d  t h a t  t h e  p a t i e n t  i s  e l i g i b l e  t o  w e a r  
t h e s e  l e n s e s ,  t h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  p r o c e e d  t o  t h e  l e n s  ﬁ  t t i n g  
i n s t r u c t i o n s  a s  o u t l i n e d  b e l o w .  
C .   I n i t i a l  P ow e r  D e t e rm i n a t i o n 
A  s p e c t a c l e  r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  
r e f r a c t i v e  s t a t u s  a n d  t o  g u i d e  i n  t h e  s e l e c t i o n  o f  t h e  a p p r o p r i a t e  l e n s  p o w e r .  
R em em b e r  t o  c om p e n s a t e  f o r  v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  t h a n  
± 4 . 0 0 D . 
D .   B a s e  C u r v e  S e l e c t i o n  ( T r i a l  L e n s  F i t t i n g ) 
T h e  f o l l o w i n g  t r i a l  l e n s e s  s h o u l d  b e  s e l e c t e d  f o r  p a t i e n t s  r e g a r d l e s s  o f  
k e r a t om e t r y  r e a d i n g s .  H o w e v e r ,  c o r n e a l  c u r v a t u r e  m e a s u r em e n t s  s h o u l d  b e  
p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  o c u l a r  s t a t u s .  
1 2 
C R - 6 3 7 2 ,  v  2 . 0 )  
 
P a g e  1 2 8  o f  2 2 5 J V C  CO N F I D E N T I A L 
•  1 - D A Y  A C U V U E ® M O I S T :  8 . 5  mm / 1 4 . 2  mm 
•  1 - D A Y  A C U V U E ® M O I S T  f o r  A S T I GM A T I SM :  8 . 5  mm / 1 4 . 5  mm 
•  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L :  8 . 4  mm / 1 4 . 3  mm 
T h e  t r i a l  l e n s  s h o u l d  b e  p l a c e d  o n  e a c h  o f  t h e  p a t i e n t ’ s  e y e s  a n d  e v a l u a t e d  
a f t e r  t h e  p a t i e n t  h a s  a d j u s t e d  t o  t h e  l e n s e s . 
1 .   C r i t e r i a  o f  a  P r o p e r l y  F i t  L e n s 
A  p r o p e r l y  ﬁ  t  l e n s  w i l l  c e n t e r  a n d  c om p l e t e l y  c o v e r  t h e  c o r n e a  ( i . e . ,  n o  
l im b a l  e x p o s u r e ) ,  h a v e  s u f ﬁ  c i e n t  m o v em e n t  t o  p r o v i d e  t e a r  e x c h a n g e  
u n d e r  t h e  c o n t a c t  l e n s  w i t h  t h e  b l i n k ,  a n d  b e  c om f o r t a b l e .  T h e  l e n s  
s h o u l d  m o v e  f r e e l y  w h e n  m a n i p u l a t e d  d i g i t a l l y  w i t h  t h e  l o w e r  l i d ,  a n d  t h e n  
r e t u r n  t o  i t s  p r o p e r l y  c e n t e r e d  p o s i t i o n  w h e n  r e l e a s e d . 
2 .   C r i t e r i a  o f  a  F l a t  F i t t i n g  L e n s 
A  ﬂ  a t  ﬁ  t t i n g  l e n s  m a y  e x h i b i t  o n e  o r  m o r e  o f  t h e  f o l l o w i n g  c h a r a c t e r i s t i c s :  
d e c e n t r a t i o n ,  i n c om p l e t e  c o r n e a l  c o v e r a g e  ( i . e . ,  l im b a l  e x p o s u r e ) ,  
e x c e s s i v e  m o v em e n t  w i t h  t h e  b l i n k  a n d / o r  e d g e  s t a n d o f f .  I f  t h e  l e n s  i s  
j u d g e d  t o  b e  ﬂ  a t  ﬁ  t t i n g ,  i t  s h o u l d  n o t  b e  d i s p e n s e d  t o  t h e  p a t i e n t . 
3 .   C r i t e r i a  o f  a  S t e e p  F i t t i n g  L e n s 
A  s t e e p  ﬁ  t t i n g  l e n s  m a y  e x h i b i t  o n e  o r  m o r e  o f  t h e  f o l l o w i n g  
c h a r a c t e r i s t i c s :  i n s u f ﬁ  c i e n t  m o v em e n t  w i t h  t h e  b l i n k ,  c o n j u n c t i v a l  
i n d e n t a t i o n ,  a n d  r e s i s t a n c e  w h e n  p u s h i n g  t h e  l e n s  u p  d i g i t a l l y  w i t h  
t h e  l o w e r  l i d .  I f  t h e  l e n s  i s  j u d g e d  t o  b e  s t e e p  ﬁ  t t i n g ,  i t  s h o u l d  n o t  b e  
d i s p e n s e d  t o  t h e  p a t i e n t . 
I f  t h e  i n i t i a l  t r i a l  b a s e  c u r v e  i s  j u d g e d  t o  b e  ﬂ  a t  o r  s t e e p  ﬁ  t t i n g ,  t h e  a l t e r n a t e  
b a s e  c u r v e ,  i f  a v a i l a b l e ,  s h o u l d  b e  t r i a l  ﬁ  t  a n d  e v a l u a t e d  a f t e r  t h e  p a t i e n t  h a s  
a d j u s t e d  t o  t h e  l e n s .  T h e  l e n s  s h o u l d  m o v e  f r e e l y  w h e n  m a n i p u l a t e d  d i g i t a l l y  
w i t h  t h e  l o w e r  l i d ,  a n d  t h e n  r e t u r n  t o  a  p r o p e r l y  c e n t e r e d  p o s i t i o n  w h e n  
r e l e a s e d .  I f  r e s i s t a n c e  i s  e n c o u n t e r e d  w h e n  p u s h i n g  t h e  l e n s  u p ,  t h e  l e n s  i s  
ﬁ  t t i n g  t i g h t l y  a n d  s h o u l d  n o t  b e  d i s p e n s e d  t o  t h e  p a t i e n t . 
E .   F i n a l  L e n s  P ow e r  ( S p h e r i c a l ) 
A  s p h e r i c a l  o v e r - r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  
p o w e r  a f t e r  t h e  l e n s  ﬁ  t  i s  j u d g e d  a c c e p t a b l e .  T h e  s p h e r i c a l  o v e r - r e f r a c t i o n  
s h o u l d  b e  c om b i n e d  w i t h  t h e  t r i a l  l e n s  p o w e r  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  
p r e s c r i p t i o n .  T h e  p a t i e n t  s h o u l d  e x p e r i e n c e  g o o d  v i s u a l  a c u i t y  w i t h  t h e  
c o r r e c t  l e n s  p o w e r  u n l e s s  t h e r e  i s  e x c e s s i v e  r e s i d u a l  a s t i gm a t i sm . 
1 3 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 2 9  o f  2 2 5 J V C  CO N F I D E N T I A L 
E x am p l e  1 
D i a g n o s t i c  l e n s : - 2 . 0 0 D 
S p h e r i c a l  o v e r - r e f r a c t i o n :   - 0 . 2 5 D 
F i n a l  l e n s  p o w e r :   - 2 . 2 5 D 
E x am p l e  2 
D i a g n o s t i c  l e n s : - 2 . 0 0 D 
S p h e r i c a l  o v e r - r e f r a c t i o n :  + 0 . 2 5 D 
F i n a l  l e n s  p o w e r :  - 1 . 7 5 D 
I f  v i s i o n  i s  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  ﬁ  t  
( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  t h e  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  a n d  
i n s t r u c t  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  P A T I E N T  
M A N A G EM E N T  s e c t i o n ) . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
A l t h o u g h  m o s t  a s p e c t s  o f  t h e  ﬁ  t t i n g  p r o c e d u r e  a r e  i d e n t i c a l  f o r  a l l  t y p e s  o f  s o f t  
c o n t a c t  l e n s e s ,  i n c l u d i n g  t o r i c  l e n s e s ,  t h e r e  a r e  s om e  a d d i t i o n a l  s t e p s  a n d / o r  
r u l e s  t o  f o l l o w  t o  a s s u r e  t h e  p r o p e r  ﬁ  t  o f  t o r i c  l e n s e s .  
T h e  o n l y  n e w  s t e p s  y o u  m u s t  f o l l o w  i n  p r e s c r i b i n g  1 - D A Y  A C U V U E ® M O I S T  
f o r  A S T I GM A T I SM  a r e  t h a t  y o u  m u s t  d e t e rm i n e  t h e  s t a b i l i t y ,  r e p e a t a b i l i t y ,  a n d  
d r i f t  a n g l e  o f  t h e  l e n s  a x i s  s o  t h a t  y o u  c a n  p r e s c r i b e  t h e  c o r r e c t  l e n s  a x i s  f o r  t h e  
p a t i e n t .  
A .  H ow  t o  D e t e rm i n e  L e n s  C y l i n d e r  a n d  A x i s  O r i e n t a t i o n 
1 .    L o c a t e  t h e  O r i e n t a t i o n  M a r k s  
T o  h e l p  d e t e rm i n e  t h e  p r o p e r  o r i e n t a t i o n  o f  t h e  t o r i c  l e n s ,  y o u ’ l l  ﬁ  n d  t w o  
p r im a r y  m a r k s  a p p r o x im a t e l y  1  mm  f r om  t h e  l e n s  e d g e  r e p r e s e n t i n g  t h e  
v e r t i c a l  p o s i t i o n  o n  o p p o s i t e  e n d s  o f  t h e  l e n s  a t  6  a n d  1 2  o ’ c l o c k  ( F i g .  1 ) .  
B e c a u s e  o f  t h e  l e n s ’  b a l l a s t i n g  s y s t em ,  e i t h e r  m a r k  c a n  r e p r e s e n t  t h e  v e r - 
t i c a l  p o s i t i o n  –  t h e r e  i s  n o  “ t o p ”  a n d  “ b o t t om ”  a s  i n  a  p r i sm - b a l l a s t e d  l e n s .  
Y o u  d o n ’ t  n e e d  t o  v i e w  b o t h  m a r k s  t o  a s s e s s  o r i e n t a t i o n ;  s im p l y  l o o k  f o r  t h e  
6  o ’ c l o c k  m a r k  a s  y o u  w o u l d  w i t h  a  p r i sm - b a l l a s t e d  l e n s . TO R I C  F I T T I NG  G U I D E L I N E S 
1 4 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 0  o f  2 2 5 J V C  CO N F I D E N T I A L 
     F i g u r e  1 
Y o u ’ l l  n e e d  a  s l i t  l am p  b i om i c r o s c o p e  w i t h  a  1  t o  2  mm  p a r a l l e l e p i p e d  
b e am  t o  h i g h l i g h t  t h e  m a r k s  w h e n  t h e  l e n s  i s  ﬁ  t t e d  t o  t h e  e y e .  T h e r e  a r e  a  
n um b e r  o f  t e c h n i q u e s  y o u  c a n  u s e  t o  im p r o v e  t h e  v i s i b i l i t y  o f  t h e  6  o ’ c l o c k  
m a r k .  U s i n g  a  p a r a l l e l e p i p e d  b e am  a n d  m e d i um  m a g n i ﬁ  c a t i o n  ( 1 0 x  o r  1 5 x ) ,  
s l o w l y  p a n  d o w n  t h e  l e n s ,  l o o k i n g  j u s t  b e l o w  t h e  d i r e c t  i l l um i n a t i o n  a t  t h e  
r e t r o i l l um i n a t e d  a r e a .  B a c k l i g h t i n g  t h e  m a r k  t h i s  w a y  s h o u l d  m a k e  i t  m o r e  
v i s i b l e .  S om e t im e s  m a n i p u l a t i n g  t h e  l o w e r  l i d  m a y  b e  n e c e s s a r y  t o  u n c o v e r  
t h e  m a r k . 
2 .    O b s e r v e  L e n s  R o t a t i o n  a n d  S t a b i l i t y  
O b s e r v e  t h e  p o s i t i o n  a n d  s t a b i l i t y  o f  t h e  “ b o t t om ”  m a r k .  I t  u s u a l l y  s t a b i l i z e s  
a t  t h e  6  o ’ c l o c k  p o s i t i o n .  I f  i t  d o e s ,  c a l c u l a t i o n  o f  t h e  l e n s  p o w e r  w i l l  b e  
s t r a i g h t f o r w a r d .  T h e  6  o ’ c l o c k  p o s i t i o n  i s  n o t  a  “m u s t ” ;  h o w e v e r ,  t h e  
a b s o l u t e  r e q u i r em e n t  i s  t h a t  t h e  a x i s  p o s i t i o n  b e  s t a b l e  a n d  r e p e a t a b l e .  
T h e  m a r k  m a y  s t a b i l i z e  s om e w h a t  l e f t  o r  r i g h t  ( d r i f t )  o f  t h e  v e r t i c a l  m e r i d i a n  
a n d  s t i l l  e n a b l e  y o u  t o  ﬁ  t  a  t o r i c  l e n s  f o r  t h a t  e y e ,  a s  l o n g  a s  t h e  l e n s  a l w a y s  
r e t u r n s  t o  t h e  s am e  “ d r i f t  a x i s ”  p o s i t i o n  a f t e r  s e t t l i n g .  T h e  d e v i a t i o n  c a n  
b e  c om p e n s a t e d  f o r  i n  t h e  ﬁ  n a l  p r e s c r i p t i o n .  Y o u r  o b j e c t i v e  i s  t o  e n s u r e  
t h a t  w h a t e v e r  p o s i t i o n  t h e  i n i t i a l  l e n s  a s s um e s  n e a r  6  o ’ c l o c k ,  t h i s  p o s i t i o n  
m u s t  b e  s t a b l e  a n d  r e p e a t a b l e .  W i t h  f u l l  e y e  m o v em e n t  o r  h e a v y  b l i n k ,  y o u  
m a y  s e e  t h e  m a r k s  s w i n g  a w a y ,  b u t  t h e y  m u s t  r e t u r n  q u i c k l y  t o  t h e  o r i g i n a l  
s t a b l e  p o s i t i o n .  I f  t h e  l e n s  d o e s  n o t  r e t u r n  q u i c k l y ,  y o u  m a y  n e e d  t o  s e l e c t  
a  d i f f e r e n t  l e n s .  
3 .   A s s e s s i n g  R o t a t i o n  
Im a g i n e  t h e  e y e  a s  a  c l o c k  d i a l  a n d  e v e r y  h o u r  r e p r e s e n t s  a  3 0 °  i n t e r v a l .  I f  
t h e  o r i e n t a t i o n  m a r k  o f  t h e  i n i t i a l  l e n s  s t a b i l i z e s  s om e w h a t  l e f t  o r  r i g h t  o f  t h e  
v e r t i c a l  p o s i t i o n ,  t h e  ﬁ  n a l  l e n s  w i l l  o r i e n t  o n  t h e  e y e  w i t h  t h e  s am e  d e v i a t i o n .  
Y o u  c a n  u s e  a n  a x i s  r e t i c u l e  i n  t h e  s l i t  l am p  o r  u s e  a  l i n e - s c r i b e d  l e n s  i n  a  
s p e c t a c l e  t r i a l  f r am e  t o  m e a s u r e  o r  e s t im a t e  t h e  “ d r i f t  a n g l e ”  o f  t h e  c y l i n d e r  
a x i s .  
T o  c om p e n s a t e  f o r  t h i s  “ d r i f t , ”  m e a s u r e  o r  e s t im a t e  t h e  “ d r i f t , ”  t h e n  a d d  
o r  s u b t r a c t  i t  f r om  t h e  r e f r a c t i v e  a x i s  t o  d e t e rm i n e  t h e  c o r r e c t  c y l i n d e r  
a x i s .  U s e  t h e  L A R S  ( L e f t  A d d ,  R i g h t  S u b t r a c t )  m e t h o d  t o  d e t e rm i n e  w h i c h  
d i r e c t i o n  t o  c om p e n s a t e .   
1 5 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 1  o f  2 2 5 J V C  CO N F I D E N T I A L 
B .  F i n a l  L e n s  P ow e r 
W h e n  t h e  d i a g n o s t i c  l e n s  h a s  i t s  a x i s  a l i g n e d  i n  t h e  s am e  m e r i d i a n  a s  t h e  
p a t i e n t ’ s  r e f r a c t i v e  a x i s ,  a  s p h e r o c y l i n d r i c a l  o v e r - r e f r a c t i o n  m a y  b e  p e r f o rm e d  
a n d  v i s u a l  a c u i t y  d e t e rm i n e d .  H o w e v e r ,  i n  t h e  c a s e  o f  c r o s s e d  a x e s ,  s u c h  a s  
w h e n  t h e  d i a g n o s t i c  l e n s  a x i s  i s  d i f f e r e n t  f r om  t h e  s p e c t a c l e  c y l i n d e r  a x i s ,  i t  i s  
n o t  a d v i s a b l e  t o  p e r f o rm  a  f u l l  s p h e r o c y l i n d r i c a l  o v e r - r e f r a c t i o n  b e c a u s e  o f  t h e  
d i f ﬁ  c u l t y  i n  c om p u t i n g  t h e  r e s u l t a n t  p o w e r .  A  s p h e r i c a l  o v e r - r e f r a c t i o n  w i t h o u t  
c y l i n d e r  r e f r a c t i o n  m a y  b e  p e r f o rm e d . 
I f  t h e  r e q u i r e d  c y l i n d e r  c o r r e c t i o n  f a l l s  b e t w e e n  t w o  a v a i l a b l e  c y l i n d e r  p o w e r s ,  
i t  i s  r e c omm e n d e d  t o  p r e s c r i b e  t h e  l o w e r  c y l i n d e r  p o w e r  l e n s .  S e e  b e l o w  f o r  
i n s t r u c t i o n s  o n  h o w  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  p o w e r . 
1 .   F o r  t h e  S p h e r e  
I f  s p h e r e  a l o n e  o r  c om b i n e d  s p h e r e  a n d  c y l i n d e r  R x  >  4 . 0 0 D ,  c om p e n s a t e  
f o r  v e r t e x  d i s t a n c e .  I f  s p h e r e  a l o n e  o r  c om b i n e d  s p h e r e  a n d  c y l i n d e r  
R x  <  ± 4 . 0 0 D ,  v e r t e x  c om p e n s a t i o n  i s  n o t  n e c e s s a r y . 
2 .   F o r  t h e  C y l i n d e r 
A d j u s t  t h e  a x i s  b y  t h e  d r i f t  a n g l e  u s i n g  t h e  L A R S  m e t h o d .  C h o o s e  a  c y l i n d e r  
t h a t  i s  ≤  0 . 5 0 D  f r om  t h e  r e f r a c t i v e  c y l i n d e r . 
3 .   C a s e  E x am p l e s 
E x am p l e  1 
M a n i f e s t  ( s p e c t a c l e )  r e f r a c t i o n : 
O . D .  - 2 . 5 0 D  /  - 1 . 2 5 D  x  1 8 0 °  2 0 / 2 0 
O . S .  - 2 . 0 0 D  /  - 1 . 0 0 D  x  1 8 0 °  2 0 / 2 0 
C h o o s e  a  d i a g n o s t i c  l e n s  f o r  e a c h  e y e  w i t h  a x i s  1 8 0 ° .  P l a c e  t h e  l e n s  o n  
e a c h  e y e  a n d  a l l o w  a  m i n im um  o f  3  m i n u t e s  f o r  i t  t o  e q u i l i b r a t e ,  b a s e d  o n  
t h e  p a t i e n t ’ s  i n i t i a l  r e s p o n s e  t o  t h e  l e n s .  I f  t h e  l e n s  h a s  n o t  y e t  s t a b i l i z e d ,  
r e c h e c k  u n t i l  s t a b l e . 
C h e c k  t h e  o r i e n t a t i o n  o f  t h e  a x i s  m a r k .  I f  t h e  b o t t om  a x i s  m a r k  i s  i n  t h e  6  
o ’ c l o c k  p o s i t i o n  o n  b o t h  e y e s ,  c h o o s e  t h e  a p p r o p r i a t e  c y l i n d e r  a s  l i s t e d  
p r e v i o u s l y .  I f  t h e  l e n s  h a s  n o t  y e t  s t a b i l i z e d ,  r e c h e c k  u n t i l  s t a b l e . 
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . D .  - 2 . 5 0 D  /  - 1 . 2 5 D  x  1 8 0 ° 
O . S .  - 2 . 0 0 D  /  - 0 . 7 5 D  x  1 8 0 ° 
1 6 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 2  o f  2 2 5 J V C  CO N F I D E N T I A L 
E x am p l e  2 
M a n i f e s t  ( s p e c t a c l e )  r e f r a c t i o n : 
O . D .  - 3 . 0 0 D  /  - 1 . 0 0 D  x  9 0 °  2 0 / 2 0 
O . S .  - 4 . 7 5 D  /  - 2 . 0 0 D  x  9 0 °  2 0 / 2 0 
C h o o s e  d i a g n o s t i c  l e n s e s  o f  - 3 . 0 0 D  /  - 0 . 7 5 D  x  9 0 °  f o r  t h e  r i g h t  e y e  a n d  
- 4 . 5 0 D  /  - 1 . 7 5 D  x  9 0 °  f o r  t h e  l e f t  e y e ,  t h e  n e a r e s t  l e n s e s  a v a i l a b l e  t o  t h e  
s p h e r i c a l  p o w e r  a n d  a x i s  n e e d e d .  F o r  t h e  l e f t  e y e ,  s i n c e  t h e  m a n i f e s t  
r e f r a c t i o n  c a l l e d  f o r  - 4 . 7 5 D ,  c om p e n s a t i n g  f o r  v e r t e x  d i s t a n c e  t h e  s p h e r e  
i s  r e d u c e d  b y  0 . 2 5 D  t o  - 4 . 5 0 D .  T h e  c y l i n d e r  p o w e r  w i l l  b e  - 1 . 7 5 D .  P l a c e  
t h e  l e n s  o n  e a c h  e y e  a n d  a l l o w  a  m i n im um  o f  3  m i n u t e s  f o r  i t  t o  e q u i l i b r a t e ,  
b a s e d  o n  t h e  p a t i e n t ' s  i n i t i a l  r e s p o n s e  t o  t h e  l e n s .  I f  t h e  l e n s  h a s  n o t  y e t  
s t a b i l i z e d ,  r e c h e c k  u n t i l  s t a b l e . 
R i g h t  E y e 
T h e  o r i e n t a t i o n  m a r k  o n  t h e  r i g h t  l e n s  r o t a t e s  l e f t  f r om  t h e  6  o ’ c l o c k  p o s i t i o n  
b y  1 0 °  a n d  r em a i n s  s t a b l e  i n  t h i s  p o s i t i o n .  C om p e n s a t i o n  f o r  t h i s  r o t a t i o n  
s h o u l d  b e  d o n e  a s  f o l l o w s : 
C om p e n s a t e  t h e  1 0 °  a x i s  d r i f t  b y  a d d i n g  i t  t o  t h e  m a n i f e s t  r e f r a c t i o n  a x i s . 
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . D .  - 3 . 0 0 D  /  - 0 . 7 5 D  x  1 0 0 ° 
L e f t  E y e 
T h e  o r i e n t a t i o n  m a r k  o n  t h e  l e f t  l e n s  r o t a t e s  r i g h t  f r om  t h e  6  o ’ c l o c k  p o s i t i o n  
b y  1 0 °  a n d  r em a i n s  s t a b l e  i n  t h i s  p o s i t i o n .  C om p e n s a t i o n  f o r  t h i s  r o t a t i o n  
s h o u l d  b e  d o n e  a s  f o l l o w s : 
C om p e n s a t e  f o r  t h e  1 0 °  a x i s  d r i f t  b y  s u b t r a c t i n g  i t  f r om  t h e  m a n i f e s t  
r e f r a c t i o n  a x i s .  
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . S .  - 4 . 5 0 D  /  - 1 . 7 5 D  x  8 0 °  
I f  v i s i o n  i s  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  
ﬁ  t  ( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  
i n s t r u c t i n g  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  
P A T I E N T  M A N A G EM E N T  s e c t i o n ) . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
1 7 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 3  o f  2 2 5 J V C  CO N F I D E N T I A L 
A .   P r e s b y o p i c  N e e d s  A s s e s sm e n t  &  P a t i e n t  E d u c a t i o n 
M u l t i f o c a l  c o n t a c t  l e n s e s  m a y  p r o d u c e  c om p r om i s e  t o  v i s i o n  u n d e r  c e r t a i n  
c i r c um s t a n c e s  a n d  t h e  p a t i e n t  s h o u l d  u n d e r s t a n d  t h a t  t h e y  m i g h t  n o t  ﬁ  n d  
t h e i r  v i s i o n  a c c e p t a b l e  i n  s p e c i ﬁ  c  s i t u a t i o n s  ( i . e . ,  r e a d i n g  a  m e n u  i n  a  d im  
r e s t a u r a n t ,  d r i v i n g  a t  n i g h t  i n  r a i n y / f o g g y  c o n d i t i o n s ,  e t c . ) .  T h e r e f o r e ,  c a u t i o n  
s h o u l d  b e  e x e r c i s e d  w h e n  t h e  p a t i e n t  i s  w e a r i n g  t h e  c o r r e c t i o n  f o r  t h e  ﬁ  r s t  
t im e  u n t i l  t h e y  a r e  f am i l i a r  w i t h  t h e  v i s i o n  p r o v i d e d  i n  v i s u a l l y  c h a l l e n g i n g  
e n v i r o nm e n t s .  O c c u p a t i o n a l  a n d  e n v i r o nm e n t a l  v i s u a l  d em a n d s  s h o u l d  
b e  c o n s i d e r e d .  I f  t h e  p a t i e n t  r e q u i r e s  c r i t i c a l  v i s u a l  a c u i t y  a n d  s t e r e o p s i s ,  i t  
s h o u l d  b e  d e t e rm i n e d  b y  t r i a l  w h e t h e r  t h i s  p a t i e n t  c a n  f u n c t i o n  a d e q u a t e l y  
w i t h  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L .  W e a r i n g  t h e s e  l e n s e s  m a y  n o t  
b e  o p t im a l  f o r  a c t i v i t i e s  s u c h  a s : 
•  V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s u c h  a s  o p e r a t i n g  p o t e n t i a l l y  d a n g e r o u s  
m a c h i n e r y  o r  p e r f o rm i n g  o t h e r  p o t e n t i a l l y  h a z a r d o u s  a c t i v i t i e s ;  a n d 
•  D r i v i n g  a u t om o b i l e s  ( e . g . ,  d r i v i n g  a t  n i g h t ) .  P a t i e n t s  w h o  c a n n o t  m e e t  
t h e i r  s t a t e  d r i v e r ’ s  l i c e n s e  r e q u i r em e n t s  w i t h  t h e  1 - D A Y  A C U V U E ® M O I S T  
M U L T I F O C A L  s h o u l d  b e  a d v i s e d  t o  n o t  d r i v e  w i t h  t h i s  c o r r e c t i o n ,  O R  m a y  
r e q u i r e  t h a t  a d d i t i o n a l  o v e r - c o r r e c t i o n  b e  p r e s c r i b e d . 
1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L  i s  n o t  r e c omm e n d e d  f o r  p a t i e n t s  
w h o  h a v e  - 1 . 0 0 D  o r  g r e a t e r  o f  r e f r a c t i v e  c y l i n d e r  a s  t h i s  l e v e l  o f  u n c o r r e c t e d  
c y l i n d e r  m a y  l e a d  t o  a d d i t i o n a l  v i s u a l  c om p r om i s e .  T h e s e  l e n s e s  a r e  a v a i l a b l e  
i n  t h e  f o l l o w i n g  A D D  p o w e r s :  
•  L e n s  “ L OW ”  =  l o w  n e a r  A D D  l e n s  (M a x  A D D  + 1 . 2 5 )  
•  L e n s  “M I D ”  =  m e d i um  n e a r  A D D  l e n s  (M a x  A D D  + 1 . 7 5 )  
•  L e n s  “ H G H ”  =  h i g h  n e a r  A D D  l e n s  (M a x  A D D  + 2 . 5 0 ) 
B .   I n i t i a l  P ow e r  D e t e rm i n a t i o n 
A  s p e c t a c l e  r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  
r e f r a c t i v e  s t a t u s  a n d  t o  g u i d e  i n  t h e  s e l e c t i o n  o f  t h e  a p p r o p r i a t e  l e n s  p o w e r .  
R em em b e r  t o  c om p e n s a t e  f o r  v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  
t h a n  ± 4 . 0 0 D .  D e t e rm i n e  t h e  s p h e r i c a l  e q u i v a l e n t  d i s t a n c e  p r e s c r i p t i o n  f o r  a  
m u l t i f o c a l  p a t i e n t .  D e t e rm i n e  t h e  e y e  d om i n a n c e  u s i n g  o n e  o f  t h e  m e t h o d s  
b e l o w : M U L T I FO C A L  F I T T I NG  G U I D E L I N E S 
1 8 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 4  o f  2 2 5 J V C  CO N F I D E N T I A L 
M e t h o d  1     D e t e rm i n e  w h i c h  e y e  i s  t h e  “ s i g h t i n g  e y e . ”  H a v e  t h e  p a t i e n t  p o i n t  
t o  a n  o b j e c t  a t  t h e  f a r  e n d  o f  t h e  r o om .  C o v e r  o n e  e y e .  I f  t h e  
p a t i e n t  i s  s t i l l  p o i n t i n g  d i r e c t l y  a t  t h e  o b j e c t ,  t h e  e y e  b e i n g  u s e d  i s  
t h e  d om i n a n t  ( s i g h t i n g )  e y e . 
M e t h o d  2     D e t e rm i n e  w h i c h  e y e  d o e s  n o t  a c c e p t  a d d e d  p l u s  p o w e r .  P l a c e  a  
+ 1 . 0 0 D  h a n d - h e l d  t r i a l  l e n s  i n  f r o n t  o f  o n e  e y e  a n d  t h e n  t h e  o t h e r  
w h i l e  t h e  d i s t a n c e  r e f r a c t i v e  e r r o r  c o r r e c t i o n  i s  i n  p l a c e  f o r  b o t h  
e y e s  w h i l e  t h e  p a t i e n t  i s  v i e w i n g  t h e  d i s t a n c e  v i s u a l  a c u i t y  c h a r t .  
T h e  e y e  w i t h  t h e  p l u s  o v e r  i t  t h a t  t h e  p a t i e n t  n o t i c e s  t h e  g r e a t e s t  
r e d u c t i o n  i n  v i s i o n  i s  d e t e rm i n e d  t o  b e  t h e  d om i n a n t  e y e . 
C .  S e l e c t  t h e  I n i t i a l  T r i a l  L e n s  
1 .   F o r  e a c h  e y e ,  s e l e c t  t h e  t r i a l  l e n s  d i s t a n c e  p o w e r  t h a t  i s  c l o s e s t  t o  t h e  
p a t i e n t ’ s  d i s t a n c e  s p h e r i c a l  e q u i v a l e n t .  R em em b e r  t o  c om p e n s a t e  f o r  
v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  t h a n  ± 4 . 0 0 D . 
2 .   S e l e c t  t h e  n e a r  p o w e r  o f  t h e  l e n s  b a s e d  o n  t h e  p a t i e n t s  A D D  r a n g e  a s  
f o l l o w s :  
•  A D D :  + 0 . 7 5 D  t o  + 1 . 2 5 D  u s e  a  l o w  n e a r  A D D  ( L OW )  l e n s  o n  e a c h  e y e  
•  A D D :  + 1 . 5 0 D  t o  + 1 . 7 5 D  u s e  a  m e d i um  n e a r  A D D  (M I D )  l e n s  o n  e a c h  
e y e  
•  A D D :  + 2 . 0 0 D  t o  + 2 . 5 0 D  u s e  a  m e d i um  n e a r  A D D  (M I D )  o n  t h e  
d om i n a n t  e y e  a n d  a  h i g h  n e a r  A D D  ( H G H )  l e n s  o n  t h e  n o n - d om i n a n t  
e y e 
3 .   A l l o w  t h e  l e n s e s  t o  s e t t l e  f o r  a  m i n im um  o f  1 0  m i n u t e s .  
4 .   A s s e s s  d i s t a n c e  a n d  n e a r  v i s i o n  b i n o c u l a r l y  a n d  m o n o c u l a r l y .  
5 .   D em o n s t r a t e  t h e  v i s i o n  u n d e r  v a r i o u s  l i g h t i n g  c o n d i t i o n s  ( n o rm a l  a n d  
d e c r e a s e d  i l l um i n a t i o n )  a n d  a t  d i s t a n c e ,  i n t e rm e d i a t e ,  a n d  n e a r .  
6 .   M a k e  a d j u s tm e n t s  i n  p o w e r  a s  n e c e s s a r y  b a s e d  o n  t h e  d i s t a n c e  o v e r - 
r e f r a c t i o n .  T h e  u s e  o f  h a n d - h e l d  t r i a l  l e n s e s  i s  r e c omm e n d e d .  C h e c k  t h e  
im p a c t  o n  d i s t a n c e  a n d  n e a r  v i s i o n . 
7 .  I f  v i s i o n  i s  s t i l l  u n a c c e p t a b l e ,  m a k e  a d j u s tm e n t s  i n  p o w e r  a s  n e c e s s a r y  
( s e e  "M u l t i f o c a l  T r o u b l e s h o o t i n g "  b e l o w ) .  I f  d i s t a n c e  a n d  n e a r  v i s i o n  
a r e  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  
ﬁ  t  ( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  
i n s t r u c t i n g  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  
P A T I E N T  M A N A G EM E N T  s e c t i o n ) . 
1 9 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 5  o f  2 2 5 J V C  CO N F I D E N T I A L 
D .  M u l t i f o c a l  T r o u b l e s h o o t i n g 
U n a c c e p t a b l e  N e a r  V i s i o n 
I f  i t  h a s  b e e n  d e t e rm i n e d  t h a t  n o  c h a n g e  i s  r e q u i r e d  b a s e d  o n  t h e  o v e r - 
r e f r a c t i o n ,  t h e n  a d d  + 0 . 2 5 D  t o  t h e  s p h e r i c a l  p o w e r  o f  t h e  n o n - d om i n a n t  e y e . 
U n a c c e p t a b l e  D i s t a n c e  V i s i o n 
I f  i t  h a s  b e e n  d e t e rm i n e d  t h a t  n o  c h a n g e  i s  r e q u i r e d  b a s e d  o n  t h e  o v e r - 
r e f r a c t i o n ,  t h e n  m a k e  t h e  c h a n g e s  a s  l i s t e d  b e l o w : 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  t w o  " L OW "  A D D  l e n s e s ,  c h a n g e  t h e  d om i n a n t  
e y e  t o  a  1 - D A Y  A C U V U E ® M O I S T  s p h e r e  l e n s  w i t h  a  p o w e r  e q u a l  t o  t h e  
s p h e r i c a l  e q u i v a l e n t  d i s t a n c e  p r e s c r i p t i o n . 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  t w o  "M I D "  A D D  l e n s e s ,  c h a n g e  t h e  A D D  p o w e r  i n  
t h e  d om i n a n t  e y e  t o  t h e  " L OW "  A D D  p o w e r . 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  a  "M I D "  A D D  l e n s  i n  t h e  d om i n a n t  e y e  a n d  a  
" H G H "  A D D  l e n s  i n  t h e  n o n - d om i n a n t  e y e ,  c h a n g e  t h e  n o n - d om i n a n t  e y e  
t o  a  "M I D "  A D D  l e n s  a n d  a d d  + 0 . 2 5 D  t o  t h e  d i s t a n c e  p o w e r . 
E .  A d a p t a t i o n 
V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s h o u l d  b e  a v o i d e d  d u r i n g  t h e  i n i t i a l  w e a r i n g  
p e r i o d .  A  p a t i e n t  m a y  a t  ﬁ  r s t  e x p e r i e n c e  s om e  m i l d  b l u r r e d  v i s i o n ,  d i z z i n e s s ,  
h e a d a c h e s  a n d  a  f e e l i n g  o f  s l i g h t  im b a l a n c e .  Y o u  s h o u l d  e x p l a i n  t h e  
a d a p t a t i o n a l  s ym p t om s  t o  t h e  p a t i e n t .  T h e s e  s ym p t om s  m a y  l a s t  f o r  a  b r i e f  
m i n u t e  o r  f o r  s e v e r a l  w e e k s .  T h e  l o n g e r  t h e s e  s ym p t om s  p e r s i s t ,  t h e  p o o r e r  
t h e  p r o g n o s i s  f o r  s u c c e s s f u l  a d a p t a t i o n . 
T o  h e l p  i n  t h e  a d a p t a t i o n  p r o c e s s ,  t h e  p a t i e n t  c a n  b e  a d v i s e d  t o  ﬁ  r s t  u s e  t h e  
l e n s e s  i n  a  c om f o r t a b l e ,  f am i l i a r  e n v i r o nm e n t  s u c h  a s  i n  t h e  h om e . 
S om e  p a t i e n t s  f e e l  t h a t  a u t om o b i l e  d r i v i n g  p e r f o rm a n c e  m a y  n o t  b e  o p t im a l  
d u r i n g  t h e  a d a p t a t i o n  p r o c e s s .  T h i s  i s  p a r t i c u l a r l y  t r u e  w h e n  d r i v i n g  a t  n i g h t .  
B e f o r e  d r i v i n g  a  m o t o r  v e h i c l e ,  i t  m a y  b e  r e c omm e n d e d  t h a t  t h e  p a t i e n t  b e  
a  p a s s e n g e r  ﬁ  r s t  t o  m a k e  s u r e  t h a t  t h e i r  v i s i o n  i s  s a t i s f a c t o r y  f o r  o p e r a t i n g  
a n  a u t om o b i l e .  D u r i n g  t h e  ﬁ  r s t  s e v e r a l  w e e k s  o f  w e a r  ( w h e n  a d a p t a t i o n  i s  
o c c u r r i n g ) ,  i t  m a y  b e  a d v i s a b l e  f o r  t h e  p a t i e n t  t o  o n l y  d r i v e  d u r i n g  o p t im a l  
d r i v i n g  c o n d i t i o n s .  A f t e r  a d a p t a t i o n  a n d  s u c c e s s  w i t h  t h e s e  a c t i v i t i e s ,  t h e  
p a t i e n t  s h o u l d  b e  a b l e  t o  d r i v e  u n d e r  o t h e r  c o n d i t i o n s  w i t h  c a u t i o n . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
2 0 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 6  o f  2 2 5 J V C  CO N F I D E N T I A L 
A .  P a t i e n t  S e l e c t i o n 
1 .  M o n o v i s i o n  N e e d s  A s s e s sm e n t 
F o r  a  g o o d  p r o g n o s i s ,  t h e  p a t i e n t  s h o u l d  h a v e  a d e q u a t e l y  c o r r e c t e d  
d i s t a n c e  a n d  n e a r  v i s u a l  a c u i t y  i n  e a c h  e y e .  T h e  am b l y o p i c  p a t i e n t  o r  t h e  
p a t i e n t  w i t h  s i g n i ﬁ  c a n t  a s t i gm a t i sm  ( g r e a t e r  t h a n  1 . 0 0 D )  i n  o n e  e y e  m a y  n o t  
b e  a  g o o d  c a n d i d a t e  f o r  m o n o v i s i o n  c o r r e c t i o n  w i t h  t h e s e  l e n s e s . 
O c c u p a t i o n a l  a n d  e n v i r o nm e n t a l  v i s u a l  d em a n d s  s h o u l d  b e  c o n s i d e r e d .  
I f  t h e  p a t i e n t  r e q u i r e s  c r i t i c a l  v i s i o n  ( v i s u a l  a c u i t y  a n d  s t e r e o p s i s ) ,  i t  s h o u l d  
b e  d e t e rm i n e d  b y  t r i a l  w h e t h e r  t h i s  p a t i e n t  c a n  f u n c t i o n  a d e q u a t e l y  w i t h  
m o n o v i s i o n  c o r r e c t i o n .  M o n o v i s i o n  c o n t a c t  l e n s  w e a r  m a y  n o t  b e  o p t im a l  
f o r  a c t i v i t i e s  s u c h  a s : 
•  V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s u c h  a s  o p e r a t i n g  p o t e n t i a l l y  d a n g e r o u s  
m a c h i n e r y  o r  p e r f o rm i n g  o t h e r  p o t e n t i a l l y  h a z a r d o u s  a c t i v i t i e s ;  a n d 
•  D r i v i n g  a u t om o b i l e s  ( e . g . ,  d r i v i n g  a t  n i g h t ) .  P a t i e n t s  w h o  c a n n o t  m e e t  
t h e i r  s t a t e  d r i v e r ’ s  l i c e n s e  r e q u i r em e n t s  w i t h  m o n o v i s i o n  c o r r e c t i o n  
s h o u l d  b e  a d v i s e d  t o  n o t  d r i v e  w i t h  t h i s  c o r r e c t i o n ,  O R  m a y  r e q u i r e  t h a t  
a d d i t i o n a l  o v e r - c o r r e c t i o n  b e  p r e s c r i b e d . 
2 .  P a t i e n t  E d u c a t i o n 
A l l  p a t i e n t s  d o  n o t  f u n c t i o n  e q u a l l y  w e l l  w i t h  m o n o v i s i o n  c o r r e c t i o n .  P a t i e n t s  
m a y  n o t  p e r f o rm  a s  w e l l  f o r  c e r t a i n  t a s k s  w i t h  t h i s  c o r r e c t i o n  a s  t h e y  h a v e  
w i t h  s p e c t a c l e s  (m u l t i f o c a l ,  b i f o c a l ,  t r i f o c a l ,  r e a d e r s ,  p r o g r e s s i v e s ) .  E a c h  
p a t i e n t  s h o u l d  u n d e r s t a n d  t h a t  m o n o v i s i o n ,  a s  w e l l  a s  o t h e r  p r e s b y o p i c  
a l t e r n a t i v e s ,  c a n  c r e a t e  a  v i s i o n  c om p r om i s e  t h a t  m a y  r e d u c e  v i s u a l  a c u i t y  
a n d  d e p t h  p e r c e p t i o n  f o r  d i s t a n c e  a n d  n e a r  t a s k s .  T h e r e f o r e ,  c a u t i o n  
s h o u l d  b e  e x e r c i s e d  w h e n  t h e  p a t i e n t  i s  w e a r i n g  t h e  c o r r e c t i o n  f o r  t h e  ﬁ  r s t  
t im e  u n t i l  t h e y  a r e  f am i l i a r  w i t h  t h e  v i s i o n  p r o v i d e d  i n  v i s u a l l y  c h a l l e n g i n g  
e n v i r o nm e n t s  ( e . g . ,  r e a d i n g  a  m e n u  i n  a  d im l y  l i t  r e s t a u r a n t ,  d r i v i n g  a t  n i g h t  
i n  r a i n y / f o g g y  c o n d i t i o n s ,  e t c . ) .  D u r i n g  t h e  ﬁ  t t i n g  p r o c e s s ,  i t  i s  n e c e s s a r y  f o r  
t h e  p a t i e n t  t o  r e a l i z e  t h e  d i s a d v a n t a g e s  a s  w e l l  a s  t h e  a d v a n t a g e s  o f  c l e a r  
n e a r  v i s i o n ,  a n d  s t r a i g h t  a h e a d  a n d  u p w a r d  g a z e  t h a t  m o n o v i s i o n  c o n t a c t  
l e n s e s  p r o v i d e . MO NO V I S IO N  F I T T I NG  G U I D E L I N E S 
2 1 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 7  o f  2 2 5 J V C  CO N F I D E N T I A L 
B .  E y e  S e l e c t i o n 
1 .   O c u l a r  P r e f e r e n c e  D e t e rm i n a t i o n  M e t h o d s 
G e n e r a l l y ,  t h e  n o n - d om i n a n t  e y e  i s  c o r r e c t e d  f o r  n e a r  v i s i o n .  T h e  f o l l o w i n g  
t w o  m e t h o d s  f o r  e y e  d om i n a n c e  c a n  b e  u s e d . 
M e t h o d  1     D e t e rm i n e  w h i c h  e y e  i s  t h e  “ s i g h t i n g  e y e . ”  H a v e  t h e  p a t i e n t  
p o i n t  t o  a n  o b j e c t  a t  t h e  f a r  e n d  o f  t h e  r o om .  C o v e r  o n e  e y e .  
I f  t h e  p a t i e n t  i s  s t i l l  p o i n t i n g  d i r e c t l y  a t  t h e  o b j e c t ,  t h e  e y e  
b e i n g  u s e d  i s  t h e  d om i n a n t  ( s i g h t i n g )  e y e . 
M e t h o d  2     D e t e rm i n e  w h i c h  e y e  w i l l  a c c e p t  t h e  a d d e d  p o w e r  w i t h  t h e  
l e a s t  r e d u c t i o n  i n  v i s i o n .  P l a c e  a  h a n d - h e l d  t r i a l  l e n s  e q u a l  t o  
t h e  s p e c t a c l e  n e a r  A D D  i n  f r o n t  o f  o n e  e y e  a n d  t h e n  t h e  o t h e r  
w h i l e  t h e  d i s t a n c e  r e f r a c t i v e  e r r o r  c o r r e c t i o n  i s  i n  p l a c e  f o r  
b o t h  e y e s .  D e t e rm i n e  w h e t h e r  t h e  p a t i e n t  f u n c t i o n s  b e s t  w i t h  
t h e  n e a r  A D D  l e n s  o v e r  t h e  r i g h t  o r  l e f t  e y e . 
2 .   O t h e r  E y e  S e l e c t i o n  M e t h o d s 
O t h e r  m e t h o d s  i n c l u d e  t h e  “ R e f r a c t i v e  E r r o r  M e t h o d ”  a n d  t h e  “ V i s u a l  
D em a n d s  M e t h o d . ” 
R e f r a c t i v e  E r r o r  M e t h o d 
F o r  a n i s om e t r o p i c  c o r r e c t i o n ,  i t  i s  g e n e r a l l y  b e s t  t o  ﬁ  t  t h e  m o r e  h y p e r o p i c  
( l e s s  m y o p i c )  e y e  f o r  d i s t a n c e  a n d  t h e  m o r e  m y o p i c  ( l e s s  h y p e r o p i c )  e y e  
f o r  n e a r . 
V i s u a l  D em a n d s  M e t h o d 
C o n s i d e r  t h e  p a t i e n t ’ s  o c c u p a t i o n  d u r i n g  t h e  e y e  s e l e c t i o n  p r o c e s s  t o  
d e t e rm i n e  t h e  c r i t i c a l  v i s i o n  r e q u i r em e n t s .  I f  a  p a t i e n t ’ s  g a z e  f o r  n e a r  t a s k s  
i s  u s u a l l y  i n  o n e  d i r e c t i o n ,  c o r r e c t  t h e  e y e  o n  t h a t  s i d e  f o r  n e a r . 
E x am p l e :  A  s e c r e t a r y  w h o  p l a c e s  c o p y  t o  t h e  l e f t  s i d e  o f  t h e  d e s k  w i l l  
f u n c t i o n  b e s t  w i t h  t h e  n e a r  l e n s  o n  t h e  l e f t  e y e . 
C .   S p e c i a l  F i t t i n g  C h a r a c t e r i s t i c s 
1 .   U n i l a t e r a l  V i s i o n  C o r r e c t i o n 
T h e r e  a r e  c i r c um s t a n c e s  w h e r e  o n l y  o n e  c o n t a c t  l e n s  i s  r e q u i r e d .  A s  a n  
e x am p l e ,  a n  emm e t r o p i c  p a t i e n t  w o u l d  o n l y  r e q u i r e  a  n e a r  l e n s ,  w h e r e a s  
a  b i l a t e r a l  m y o p e  w o u l d  r e q u i r e  c o r r e c t i v e  l e n s e s  o n  b o t h  e y e s .  
2 2 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 8  o f  2 2 5 J V C  CO N F I D E N T I A L 
E x am p l e s : 
A  p r e s b y o p i c  emm e t r o p i c  p a t i e n t  w h o  r e q u i r e s  a  + 1 . 7 5 D  A D D  w o u l d  
h a v e  a  + 1 . 7 5 D  l e n s  o n  t h e  n e a r  e y e  a n d  t h e  o t h e r  e y e  l e f t  w i t h o u t  
c o r r e c t i o n . 
A  p r e s b y o p i c  p a t i e n t  r e q u i r i n g  a  + 1 . 5 0 D  A D D  w h o  i s  - 2 . 5 0 D  m y o p i c  i n  
t h e  r i g h t  e y e  a n d  - 1 . 5 0 D  m y o p i c  i n  t h e  l e f t  e y e  m a y  h a v e  t h e  r i g h t  e y e  
c o r r e c t e d  f o r  d i s t a n c e  a n d  t h e  l e f t  e y e  u n c o r r e c t e d  f o r  n e a r . 
2 .   N e a r  A D D  D e t e rm i n a t i o n 
A l w a y s  p r e s c r i b e  t h e  l e n s  p o w e r  f o r  t h e  n e a r  e y e  t h a t  p r o v i d e s  o p t im a l  
n e a r  a c u i t y  a t  t h e  m i d p o i n t  o f  t h e  p a t i e n t ’ s  h a b i t u a l  r e a d i n g  d i s t a n c e .  
H o w e v e r ,  w h e n  m o r e  t h a n  o n e  p o w e r  p r o v i d e s  o p t im a l  r e a d i n g  
p e r f o rm a n c e ,  p r e s c r i b e  t h e  l e a s t  p l u s  (m o s t  m i n u s )  o f  t h e  p o w e r s . 
3 .   T r i a l  L e n s  F i t t i n g 
A  t r i a l  ﬁ  t t i n g  i s  p e r f o rm e d  i n  t h e  o f ﬁ  c e  t o  a l l o w  t h e  p a t i e n t  t o  e x p e r i e n c e  
m o n o v i s i o n  c o r r e c t i o n .  L e n s e s  a r e  ﬁ  t  a c c o r d i n g  t o  t h e  G E N E R A L  
F I T T I N G  G U I D E L I N E S  f o r  b a s e  c u r v e  s e l e c t i o n  d e s c r i b e d  i n  t h i s  
P a c k a g e  I n s e r t . 
C a s e  h i s t o r y  a n d  a  s t a n d a r d  c l i n i c a l  e v a l u a t i o n  p r o c e d u r e  s h o u l d  b e  u s e d  
t o  d e t e rm i n e  t h e  p r o g n o s i s .  D e t e rm i n e  t h e  d i s t a n c e  c o r r e c t i o n  a n d  t h e  
n e a r  c o r r e c t i o n .  N e x t ,  d e t e rm i n e  t h e  n e a r  A D D .  W i t h  t r i a l  l e n s e s  o f  t h e  
p r o p e r  p o w e r  i n  p l a c e ,  o b s e r v e  t h e  r e a c t i o n  t o  t h i s  m o d e  o f  c o r r e c t i o n . 
A l l o w  t h e  l e n s e s  t o  s e t t l e  f o r  a b o u t  2 0  m i n u t e s  w i t h  t h e  c o r r e c t  p o w e r  
l e n s e s  i n  p l a c e .  W a l k  a c r o s s  t h e  r o om  a n d  h a v e  t h e  p a t i e n t  l o o k  a t  
y o u .  A s s e s s  t h e  p a t i e n t ’ s  r e a c t i o n  t o  d i s t a n c e  v i s i o n  u n d e r  t h e s e  
c i r c um s t a n c e s .  T h e n  h a v e  t h e  p a t i e n t  l o o k  a t  f am i l i a r  n e a r  o b j e c t s  s u c h  
a s  a  w a t c h  f a c e  o r  ﬁ  n g e r n a i l s .  A g a i n  a s s e s s  t h e  r e a c t i o n .  A s  t h e  p a t i e n t  
c o n t i n u e s  t o  l o o k  a r o u n d  t h e  r o om  a t  b o t h  n e a r  a n d  d i s t a n c e  o b j e c t s ,  
o b s e r v e  t h e  r e a c t i o n s .  O n l y  a f t e r  t h e s e  v i s i o n  t e s t s  a r e  c om p l e t e d ,  s h o u l d  
t h e  p a t i e n t  b e  a s k e d  t o  r e a d  p r i n t .  E v a l u a t e  t h e  p a t i e n t ’ s  r e a c t i o n  t o  l a r g e  
p r i n t  ( e . g . ,  t y p e w r i t t e n  c o p y )  a t  ﬁ  r s t  a n d  t h e n  g r a d u a t e  t o  n e w s p r i n t  a n d  
ﬁ  n a l l y  sm a l l e r  t y p e  s i z e s . 
A f t e r  t h e  p a t i e n t ’ s  p e r f o rm a n c e  u n d e r  t h e  a b o v e  c o n d i t i o n s  i s  c om p l e t e d ,  
t e s t s  o f  v i s u a l  a c u i t y  a n d  r e a d i n g  a b i l i t y  u n d e r  c o n d i t i o n s  o f  m o d e r a t e l y  
d im  i l l um i n a t i o n  s h o u l d  b e  a t t em p t e d . 
2 3 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 3 9  o f  2 2 5 J V C  CO N F I D E N T I A L 
A n  i n i t i a l  u n f a v o r a b l e  r e s p o n s e  i n  t h e  o f ﬁ  c e ,  w h i l e  i n d i c a t i v e  o f  a  g u a r d e d  
p r o g n o s i s ,  s h o u l d  n o t  imm e d i a t e l y  r u l e  o u t  a  m o r e  e x t e n s i v e  t r i a l  u n d e r  
t h e  u s u a l  c o n d i t i o n s  i n  w h i c h  a  p a t i e n t  f u n c t i o n s . 
4 .  A d a p t a t i o n 
V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s h o u l d  b e  a v o i d e d  d u r i n g  t h e  i n i t i a l  w e a r i n g  
p e r i o d .  A  p a t i e n t  m a y  a t  ﬁ  r s t  e x p e r i e n c e  s om e  m i l d  b l u r r e d  v i s i o n ,  
d i z z i n e s s ,  h e a d a c h e s ,  a n d  a  f e e l i n g  o f  s l i g h t  im b a l a n c e .  Y o u  s h o u l d  
e x p l a i n  t h e  a d a p t a t i o n a l  s ym p t om s  t o  t h e  p a t i e n t .  T h e s e  s ym p t om s  m a y  
l a s t  f o r  a  b r i e f  m i n u t e  o r  f o r  s e v e r a l  w e e k s .  T h e  l o n g e r  t h e s e  s ym p t om s  
p e r s i s t ,  t h e  p o o r e r  t h e  p r o g n o s i s  f o r  s u c c e s s f u l  a d a p t a t i o n .  
T o  h e l p  i n  t h e  a d a p t a t i o n  p r o c e s s ,  t h e  p a t i e n t  c a n  b e  a d v i s e d  t o  ﬁ  r s t  u s e  
t h e  l e n s e s  i n  a  c om f o r t a b l e ,  f am i l i a r  e n v i r o nm e n t  s u c h  a s  i n  t h e  h om e . 
S om e  p a t i e n t s  f e e l  t h a t  a u t om o b i l e  d r i v i n g  p e r f o rm a n c e  m a y  n o t  b e  
o p t im a l  d u r i n g  t h e  a d a p t a t i o n  p r o c e s s .  T h i s  i s  p a r t i c u l a r l y  t r u e  w h e n  
d r i v i n g  a t  n i g h t .  B e f o r e  d r i v i n g  a  m o t o r  v e h i c l e ,  i t  m a y  b e  r e c omm e n d e d  
t h a t  t h e  p a t i e n t  b e  a  p a s s e n g e r  ﬁ  r s t  t o  m a k e  s u r e  t h a t  t h e i r  v i s i o n  i s  
s a t i s f a c t o r y  f o r  o p e r a t i n g  a n  a u t om o b i l e .  D u r i n g  t h e  ﬁ  r s t  s e v e r a l  w e e k s  o f  
w e a r  ( w h e n  a d a p t a t i o n  i s  o c c u r r i n g ) ,  i t  m a y  b e  a d v i s a b l e  f o r  t h e  p a t i e n t  t o  
o n l y  d r i v e  d u r i n g  o p t im a l  d r i v i n g  c o n d i t i o n s .  A f t e r  a d a p t a t i o n  a n d  s u c c e s s  
w i t h  t h e s e  a c t i v i t i e s ,  t h e  p a t i e n t  s h o u l d  b e  a b l e  t o  d r i v e  u n d e r  o t h e r  
c o n d i t i o n s  w i t h  c a u t i o n . 
D .  O t h e r  S u g g e s t i o n s 
T h e  s u c c e s s  o f  t h e  m o n o v i s i o n  t e c h n i q u e  m a y  b e  f u r t h e r  im p r o v e d  b y  h a v i n g  
y o u r  p a t i e n t  f o l l o w  t h e  s u g g e s t i o n s  b e l o w : 
•  H a v e  a  t h i r d  c o n t a c t  l e n s  ( d i s t a n c e  p o w e r )  t o  u s e  w h e n  c r i t i c a l  
d i s t a n c e  v i e w i n g  i s  n e e d e d . 
•  H a v e  a  t h i r d  c o n t a c t  l e n s  ( n e a r  p o w e r )  t o  u s e  w h e n  c r i t i c a l  n e a r  
v i e w i n g  i s  n e e d e d . 
•  H a v e  s u p p l em e n t a l  s p e c t a c l e s  t o  w e a r  o v e r  t h e  m o n o v i s i o n  
c o n t a c t  l e n s e s  f o r  s p e c i ﬁ  c  v i s u a l  t a s k s  m a y  im p r o v e  t h e  s u c c e s s  o f  
m o n o v i s i o n  c o r r e c t i o n .  T h i s  i s  p a r t i c u l a r l y  a p p l i c a b l e  f o r  t h o s e  p a t i e n t s  
w h o  c a n n o t  m e e t  s t a t e  d r i v e r ’ s  l i c e n s i n g  r e q u i r em e n t s  w i t h  m o n o v i s i o n  
c o r r e c t i o n . 
•  M a k e  u s e  o f  p r o p e r  i l l um i n a t i o n  w h e n  c a r r y i n g  o u t  v i s u a l  t a s k s . 
2 4 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 4 0  o f  2 2 5 J V C  CO N F I D E N T I A L 
M o n o v i s i o n  ﬁ  t t i n g  s u c c e s s  c a n  b e  im p r o v e d  b y  t h e  f o l l o w i n g  s u g g e s t i o n s : 
•  R e v e r s e  t h e  d i s t a n c e  a n d  n e a r  e y e s  i f  a  p a t i e n t  i s  h a v i n g  t r o u b l e  
a d a p t i n g . 
•  R e ﬁ  n e  t h e  l e n s  p o w e r s  i f  t h e r e  i s  t r o u b l e  w i t h  a d a p t a t i o n .  A c c u r a t e  
l e n s  p o w e r  i s  c r i t i c a l  f o r  p r e s b y o p i c  p a t i e n t s . 
•  Em p h a s i z e  t h e  b e n e ﬁ  t s  o f  c l e a r  n e a r  v i s i o n ,  a n d  s t r a i g h t  a h e a d  a n d  
u p w a r d  g a z e  w i t h  m o n o v i s i o n . 
T h e  d e c i s i o n  t o  ﬁ  t  a  p a t i e n t  w i t h  m o n o v i s i o n  c o r r e c t i o n  i s  m o s t  a p p r o p r i a t e l y  
l e f t  t o  t h e  E y e  C a r e  P r o f e s s i o n a l  i n  c o n j u n c t i o n  w i t h  t h e  p a t i e n t  a f t e r  c a r e f u l l y  
c o n s i d e r i n g  t h e  p a t i e n t ’ s  n e e d s . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
P A T I E N T  M A N AG EM E N T 
•  F o l l o w  t h e  a c c e p t e d  s t a n d a r d  o f  c a r e  i n  ﬁ  t t i n g  a n d  f o l l o w i n g  u p  w i t h  y o u r  
p a t i e n t ,  e . g . ,  Am e r i c a n  O p t om e t r i c  A s s o c i a t i o n  s t a n d a r d  o f  c a r e .  
•  S c h e d u l e  t h e  a p p r o p r i a t e  f o l l o w - u p  e x am i n a t i o n .  
•  P r e f e r a b l y ,  a t  t h e  f o l l o w - u p  v i s i t s ,  l e n s e s  s h o u l d  h a v e  b e e n  w o r n  f o r  a t  
l e a s t  s i x  h o u r s .  
•  P r o v i d e  t h e  p a t i e n t  w i t h  a  c o p y  o f  t h e  P A T I E N T  I N S T R U C T I O N  G U I D E  f o r  
t h e s e  l e n s e s ,  w h i c h  c a n  b e  f o u n d  a t  w w w . a c u v u e . c om .  R E V I EW  T H E S E  
I N S T R U C T I O N S  W I T H  T H E  P A T I E N T  S O  T H A T  H E  O R  S H E  C L E A R L Y  
U N D E R S T A N D S  T H E  P R E S C R I B E D  W E A R I N G  A N D  R E P L A C EM E N T  
S C H E D U L E S . 
T h e  w e a r i n g  s c h e d u l e  s h o u l d  b e  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l .  
R e g u l a r  c h e c k u p s ,  a s  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l ,  a r e  a l s o  
e x t r em e l y  im p o r t a n t . 
P a t i e n t s  t e n d  t o  o v e r  w e a r  t h e  l e n s e s  i n i t i a l l y .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  
em p h a s i z e  t h e  im p o r t a n c e  o f  a d h e r i n g  t o  t h e  i n i t i a l  m a x im um  w e a r i n g  s c h e d u l e .  
M a x im um  w e a r i n g  t im e  s h o u l d  b e  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l  
b a s e d  u p o n  t h e  p a t i e n t ’ s  p h y s i o l o g i c a l  e y e  c o n d i t i o n ,  b e c a u s e  i n d i v i d u a l  
r e s p o n s e  t o  c o n t a c t  l e n s e s  v a r i e s .  W E A R I NG  S C H E D U L E 
2 5 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 4 1  o f  2 2 5 J V C  CO N F I D E N T I A L 
T h e  m a x im um  s u g g e s t e d  w e a r i n g  t im e  f o r  t h e s e  l e n s e s  i s : 
D A Y H O U R S 
1 6 - 8 
2 8 - 1 0 
3 1 0 - 1 2 
4 1 2 - 1 4 
5  a n d  a f t e r a l l  w a k i n g  h o u r s 
T h e s e  l e n s e s  a r e  i n d i c a t e d  f o r  d a i l y  d i s p o s a b l e  w e a r  a n d  s h o u l d  b e  d i s c a r d e d  
u p o n  r em o v a l . 
W h e n  d i s p o s e d  o f  a f t e r  a  s i n g l e  d a i l y  u s e ,  t h e s e  l e n s e s  m a y  r e d u c e  t h e  r i s k  o f  
d e v e l o p i n g  g i a n t  p a p i l l a r y  c o n j u n c t i v i t i s . 4
W h e n  w o r n  a s  a  d a i l y  d i s p o s a b l e  l e n s ,  t h e s e  l e n s e s  m a y  p r o v i d e  im p r o v e d  
c om f o r t  f o r  m a n y  p a t i e n t s  w h o  e x p e r i e n c e  m i l d  d i s c om f o r t  a n d  i t c h i n g  
a s s o c i a t e d  w i t h  a l l e r g i e s  d u r i n g  c o n t a c t  l e n s  w e a r ,  c om p a r e d  t o  l e n s e s  r e p l a c e d  
a t  i n t e r v a l s  o f  g r e a t e r  t h a n  2  w e e k s . 
C l i n i c a l  r e s e a r c h  h a s  s h o w n  t h a t  w h e n  w o r n  o n  a  d a i l y  d i s p o s a b l e  b a s i s ,  t h e s e  
l e n s e s  m a y  p r o v i d e  im p r o v e d  c om f o r t  f o r  2  o u t  o f  3  p a t i e n t s  w h o  r e p o r t e d  
s u f f e r i n g  f r om  d i s c om f o r t  a s s o c i a t e d  w i t h  a l l e r g i e s  d u r i n g  c o n t a c t  l e n s  w e a r . 
4  Th e  C L A O  J o u r n a l ,  J u l y  1 9 9 9 ,  V o l um e  2 5 ,  N um b e r  3 
T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  r e v i e w  w i t h  p a t i e n t s  t h a t  n o  c l e a n i n g  o r  
d i s i n f e c t i o n  i s  n e e d e d  w i t h  d a i l y  d i s p o s a b l e  l e n s e s .  P a t i e n t s  s h o u l d  a l w a y s  
d i s p o s e  o f  l e n s e s  w h e n  t h e y  a r e  r em o v e d  a n d  h a v e  r e p l a c em e n t  l e n s e s  o r  
s p e c t a c l e s  a v a i l a b l e . 
F o r  c om p l e t e  i n f o rm a t i o n  c o n c e r n i n g  c o n t a c t  l e n s  h a n d l i n g  a n d  c a r e ,  r e f e r  t o  
t h e  P A T I E N T  I N S T R U C T I O N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d o w n l o a d  a t  w w w . a c u v u e . c om .  
C a r e  f o r  S t i c k i n g  ( N o n -M o v i n g )  L e n s e s 
D u r i n g  r em o v a l ,  i f  t h e  l e n s  s t i c k s  t o  t h e  e y e ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  
t o  a p p l y  a  f e w  d r o p s  o f  t h e  r e c omm e n d e d  l u b r i c a t i n g  o r  r e w e t t i n g  s o l u t i o n  R E P L A C EM E N T  S C H E D U L E 
L E N S  C A R E  D I R E C T IO N S 
2 6 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 4 2  o f  2 2 5 J V C  CO N F I D E N T I A L 
d i r e c t l y  t o  t h e  e y e  a n d  w a i t  u n t i l  t h e  l e n s  b e g i n s  t o  m o v e  f r e e l y  o n  t h e  e y e  b e f o r e  
r em o v i n g  i t .  I f  n o n -m o v em e n t  o f  t h e  l e n s  c o n t i n u e s  a f t e r  a  f e w  m i n u t e s ,  t h e  
p a t i e n t  s h o u l d  imm e d i a t e l y  c o n s u l t  t h e  E y e  C a r e  P r o f e s s i o n a l . 
T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  i f  c h em i c a l s  o f  a n y  k i n d  ( h o u s e h o l d  
p r o d u c t s ,  g a r d e n i n g  s o l u t i o n s ,  l a b o r a t o r y  c h em i c a l s ,  e t c . )  a r e  s p l a s h e d  i n t o  
t h e  e y e s ,  t h e  p a t i e n t  s h o u l d :   F L U S H  E Y E S  IMM E D I A T E L Y  W I T H  T A P  W A T E R  
A N D  IMM E D I A T E L Y  C O N T A C T  T H E  E Y E  C A R E  P R O F E S S I O N A L  O R  V I S I T  A  
H O S P I T A L  EM E R G E N C Y  R O OM  W I T H O U T  D E L A Y . 
E a c h  U V - a b s o r b i n g  s t e r i l e  l e n s  i s  s u p p l i e d  i n  a  f o i l - s e a l e d  p l a s t i c  p a c k a g e  
c o n t a i n i n g  b u f f e r e d  s a l i n e  s o l u t i o n  w i t h  p o v i d o n e .  T h e  p l a s t i c  p a c k a g e  i s  m a r k e d  
w i t h  t h e  f o l l o w i n g :  
•  1 - D A Y  A C U V U E ® M O I S T :  b a s e  c u r v e ,  p o w e r ,  d i am e t e r ,  l o t  n um b e r ,  a n d  
e x p i r a t i o n  d a t e 
•  1 - D A Y  A C U V U E ® M O I S T  f o r  A S T I GM A T I SM :  b a s e  c u r v e ,  p o w e r ,  
d i am e t e r ,  c y l i n d e r ,  a x i s ,  l o t  n um b e r ,  a n d  e x p i r a t i o n  d a t e 
•  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L :  b a s e  c u r v e ,  p o w e r ,  d i am e t e r ,  
A D D  p o w e r ,  l o t  n um b e r ,  a n d  e x p i r a t i o n  d a t e 
A l l  s e r i o u s  a d v e r s e  e x p e r i e n c e s  a n d  a d v e r s e  r e a c t i o n s  o b s e r v e d  i n  p a t i e n t s  
w e a r i n g  t h e s e  l e n s e s  o r  e x p e r i e n c e d  w i t h  t h e s e  l e n s e s  s h o u l d  b e  r e p o r t e d  t o : 
J o h n s o n  &  J o h n s o n  V i s i o n  C a r e ,  I n c . 
7 5 0 0  C e n t u r i o n  P a r k w a y 
J a c k s o n v i l l e ,  F L  3 2 2 5 6 
U S A 
T e l :  1 - 8 0 0 - 8 4 3 - 2 0 2 0 
w w w . a c u v u e . c om EM E RG E N C I E S 
HOW  S U P P L I E D 
R E PO R T I NG  O F  A D V E R S E  R E A C T IO N S 
2 7 
C R - 6 3 7 2 ,  v  2 . 0  
 
P a g e  1 4 3  o f  2 2 5 J V C  CO N F I D E N T I A L 
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)
CR-6372, v 2.0  
 
Page 145 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D: BINOCULAR OVER REFRACTION
CR-6372, v 2.0  
 
Page 146 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX E: PRESBYOPIC SYMPTOMS QUESTIONNAIRE
CR-6372, v 2.0  
 
Page 147 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX F: OCULAR DOMINANCE
CR-6372, v 2.0  
 
Page 148 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS
CR-6372, v 2.0  
 
Page 152 of 225JVC CONFIDENTIAL
Attachment A   Efron Grading Scale for Limbal Redness (0.5 unit increments)
Page 3 of 7  
 CR-6372, v 2.0  
 
Page 155 of 225JVC CONFIDENTIAL
Attachment B Efron Grading Scale for Limbal Redness (1.0 unit in crements)
Page 4 of 7  
 CR-6372, v 2.0  
 
Page 156 of 225JVC CONFIDENTIAL
Attachment C  Efron Grading Scale for Bulbar  Redness (0.5 unit increments)
Page 5 of 7  
 CR-6372, v 2.0  
 
Page 157 of 225JVC CONFIDENTIAL
Attachment D Efron Grading Scale for Bulbar Redness (1.0 unit in crements)
Page 6 of 7  
 CR-6372, v 2.0  
 
Page 158 of 225JVC CONFIDENTIAL
Attachment E
Page 7 of 7  
 CR-6372, v 2.0  
 
Page 159 of 225JVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING 
CR-6372, v 2.0  
 
Page 160 of 225JVC CONFIDENTIAL
 
Page 3 of 4  
     
  
CR-6372, v 2.0  
 
Page 163 of 225JJVC CONFIDENTIAL
 
Page 4 of 4  
 CR-6372, v 2.0  
 
Page 164 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DETERMINATION OF NEAR ADDITION
CR-6372, v 2.0  
 
Page 165 of 225JJVC CONFIDENTIAL
Page 4 of 7    
CR-6372, v 2.0  
 
Page 169 of 225JJVC CONFIDENTIAL
Page 5 of 7  
                        
           
CR-6372, v 2.0  
 
Page 170 of 225JJVC CONFIDENTIAL
Page 6 of 7
CR-6372, v 2.0  
 
Page 171 of 225JJVC CONFIDENTIAL
Page 7 of 7Attachment B 
CR-6372, v 2.0  
 
Page 172 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE
CR-6372, v 2.0  
 
Page 173 of 225JJVC CONFIDENTIAL
 
Page 2 of 2 
  
 
CR-6372, v 2.0  
 
Page 175 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
LENS FITTING CHARACTERISTICS
CR-6372, v 2.0  
 
Page 176 of 225JJVC CONFIDENTIAL
PPage 44  oof 66  
 Attachment A Example of Lens Centration Rating
 
 
 
 
 
  
 
 
 
 
CR-6372, v 2.0  
 
Page 180 of 225JJVC CONFIDENTIAL
PPage 55  oof 66  
 Attachment B Example of Evaluation of Primary Gaze Movement
 
CR-6372, v 2.0  
 
Page 181 of 225JJVC CONFIDENTIAL
PPage 66  oof 66  
  
 
 
  
 
 
CR-6372, v 2.0  
 
Page 182 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS 
CR-6372, v 2.0  
 
Page 183 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
FRONT AND BACK SURFACE LENS DEPOSIT GRADING 
PROCEDURE
CR-6372, v 2.0  
 
Page 185 of 225JJVC CONFIDENTIAL
Page 2 of 5  
      
  
   
CR-6372, v 2.0  
 
Page 187 of 225JJVC CONFIDENTIAL
Page 4 of 5  
 Attachment B 
CR-6372, v 2.0  
 
Page 189 of 225JJVC CONFIDENTIAL
Page 5 of 5  
 Attachment C 
CR-6372, v 2.0  
 
Page 190 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS
CR-6372, v 2.0  
 
Page 191 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
BIOMICROSCOPY SCALE
CR-6372, v 2.0  
 
Page 198 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
KERATOMETRY PROCEDURE 
CR-6372, v 2.0  
 
Page 204 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DISTANCE AND NEAR VISUAL ACUITY EVALUATION
CR-6372, v 2.0  
 
Page 206 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT
PROCEDURE
CR-6372, v 2.0  
 
Page 211 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PATIENT REPORTED OUTCOMES
CR-6372, v 2.0  
 
Page 215 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
WHITE LIGHT LENS SURFACE WETTABILITY
CR-6372, v 2.0  
 
Page 217 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING
CR-6372, v 2.0  
 
Page 219 of 225JJVC CONFIDENTIAL
  
Title: Visual Acuity Chart Luminance and Room Illumination Testing
 
Page 1of5
 
CR-6372, v 2.0  
 
Page 220 of 225JJVC CONFIDENTIAL
  
Title: Visual Acuity Chart Luminance and Room Illumination Testing
 
Page 2of5
 
CR-6372, v 2.0  
 
Page 221 of 225JJVC CONFIDENTIAL
  
Title: Visual Acuity Chart Luminance and Room Illumination Testing
 
Page 4of5
 APPENDIX A: CHART LUMINANCE VERIFICATION LOG
CR-6372, v 2.0  
 
Page 223 of 225JJVC CONFIDENTIAL
  
Title: Visual Acuity Chart Luminance and Room Illumination Testing
 
Page 5of5
 APPENDIX C: CONVERSION TABLE FOR “EV’ TO “LUX” FOR ROOM ILLU MINATION
CR-6372, v 2.0  
 
Page 224 of 225JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE
Protocol Number and Title: CR-6372 Clinical Evaluation of a Reus able Multifocal Optical 
Design in a Presbyopi c Population Phase II 
Version and Date: 2.0 25 October 2019 
I have read and understand the prot ocol specified above and agr ee on its content.   
I agree to conduct this study according to ISO 14155,1GCP and ICH guidelines,2the 
Declaration of Helsinki,3United States (US) Code of Federal Regulations (CFR),4and the 
pertinent individual country law s/regulations and to comply with its obligations, subject to 
ethical and safety considerations. The Principal Investigator i s responsible for ensuring that all 
clinical site personnel, including Sub-Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical trials during and after study com pletion.
I will assure that no deviation from or changes to the protocol  will take place without prior 
agreement from the Sponsor and documented approval from the Ins titutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard( s) to the trial participants.
I am responsible for ensuring th at all clinical site personnel including Sub-Investigators adhere 
to all ICH2regulations and GCP guidelines regarding clinical trials during  and after study 
completion. All clinical site personnel involved in the conduct of this stu dy have completed Human 
Subjects Protection Training.  I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitmen ts.
I shall not disclose the information contained in this protocol  or any results obtained from this 
study without writte n authorization. 
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6372, v 2.0  
 
Page 225 of 225JJVC CONFIDENTIAL